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Abstract	
Rheumatoid	 arthritis	 (RA)	 is	 an	 autoimmune	 disease	 affecting	 joints	 due	 to	 the	 persistent	
inflammation	 of	 the	 synovial	 tissue.	 It	 affects	 1%	 of	 the	 worldwide	 population	 with	 high	
socioeconomic	costs.	Patients	usually	require	lifetime	treatments	in	order	to	prevent	late	stage	
of	the	disease,	which	leads	to	a	condition	of	disability	and	pain.	Despite	the	introduction	of	
biological	 drugs,	 Methotrexate	 (MTX)	 is	 still	 the	 gold	 standard.	 However,	 it	 shows	 some	
weakness	such	as	inefficacy	or	adverse	events	after	long	term	usage.	For	this	reason,	there	is	
the	need	to	develop	drugs	with	an	 improved	safety	profile	and	higher	therapeutic	efficacy.	
Moreover,	 it	 is	of	primary	 importance	to	develop	diagnostics	with	enhanced	sensitivity	and	
tissue	specificity.		
In	order	to	meet	these	needs,	the	purpose	of	this	work	is	to	develop	a	nanotechnological	agent	
capable	to	delivery	its	content,	such	as	drugs	or	diagnostic	tracers,	specifically	into	pathological	
joints,	avoiding	healthy	tissues.		
These	aims	have	been	achieved	exploiting	peculiar	 features	of	biodegradable	nanoparticles	
(BNPs),	 such	 as	 improved	 pharmacokinetic	 and	 bioavailability,	 associated	 with	 a	 peptide	
specific	for	the	inflamed	synovia.	Recently,	the	heterogeneity	of	the	molecules	present	in	the	
endothelium	has	allowed	to	develop	peptides	capable	to	target	vessels	of	specific	tissues.	In	
this	project,	a	cyclic	peptide	able	to	target	the	microvasculature	of	the	inflamed	synovia	has	
been	exploited	to	drive	BNPs	only	into	inflamed	joints.	
BNPs	have	been	characterized	for	their	physicochemical	features,	polymers’	toxicity	and	drug	
release.	Targeted	polymeric	nanoparticles	(tBNPs)	demonstrated,	both	in	vitro	and	in	vivo,	to	
preferentially	bind	inflamed	synovial	tissue,	and	their	accumulation	depends	on	the	degree	of	
inflammation.		
Targeted	BNPs	loaded	with	MTX	showed	higher	efficacy	compared	to	free	MTX	in	two	different	
animal	models	of	RA.	In	addition,	a	reduced	dose	of	tBNPs-MTX	demonstrated	to	maintain	its	
efficacy,	showing	fewer	side	effects	compared	with	systemic	administration	of	free	MTX.	This	
new	therapeutic	approach	provided	a	new	mechanism	of	action	from	approved	therapy	and	
suggest	potential	application	in	non-responding	patients.	
All	these	evidence	highlight	the	potential	use	of	tBNPs	as	a	biocompatible	and	adaptable	tool	
for	the	diagnosis	and	the	treatment	of	RA	showing	important	efficacy,	reduced	side	effects	and	
with	the	potential	to	enhance	the	sensitivity	of	several	imaging	technologies.	
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1.1. Rheumatoid	arthritis	
Rheumatoid	 arthritis	 (RA)	 is	 a	 systemic	 autoimmune	disease	 (Firestein	 2003)(Smolen	 et	 al.	
2007)	characterized	by	the	chronic	inflammation	of	joint	and	bone	destruction	(Aletaha	et	al.	
2010)(Smolen	 et	 al.	 2016).	 Despite	 new	 therapies	 improve	 patients’	 outcomes	 with	 RA,	
complete	 remission	 is	 still	 a	 challenge	 and	 patients	 are	 treated	 throughout	 their	 life.	
Historically	the	term	“Rheumatoid	arthritis”	was	coined	by	Alfred	Bering	Garrod	in	1859	and	
approved	by	the	American	Rheumatism	Association	(ARA)	in	1941	(Todesco	S	2002).	Cases	of	
osteoarthritis	and	ankyloses	spondylitis,	but	not	of	RA,	were	reported	from	skeletal	remains	in	
Europe	and	north	Africa	(Aceves-Avila	et	al.	1998).	Differently,	characteristic	RA	lesions	were	
found	 in	 palaeopathological	 specimens	 in	 Native	 American	 tribes	 in	 North	 America	 (19).	
Interestingly,	 in	 these	 regions	 the	 incidence	 of	 RA	 remains	 really	 high	with	 5%	 of	 disease	
incidence.	 Instead,	 the	 worldwide	 incidence	 is	 0.5-1%,	 becoming	 the	 most	 common	
autoimmune	inflammatory	arthritis	in	adults	(Helmick	et	al.	2008).	Compared	with	the	general	
population,	patients	with	RA	show	an	increased	risk	of	mortality,	mainly	due	to	an	increased	
risk	of	cardiovascular	death	(Gabriel	2008).	Depending	on	the	studied	population,	the	average	
age	 of	 the	 onset	 for	 rheumatoid	 arthritis	 ranges	 from	 early	 40s	 to	 late	 50s	 (Innala	 et	 al.	
2014)(Symmons	et	al.	2002).	The	disease	is	more	frequent	in	woman	than	in	men	with	a	ratio	
of	3	to	1	suggesting	a	pathological	role	of	hormonal	factors	(Scott	et	al.	2010).	The	RA	burden	
is	characterized	by	direct	and	indirect	costs.	The	direct	costs	associated	with	the	treatments	
have	increased	in	the	last	20	years	due	to	the	introduction	of	biological	drugs.	Despite	these	
drugs	 improve	 patients’	 quality	 of	 life,	 the	 indirect	 costs	 are	 still	 high	 due	 to	 the	 loss	 of	
productivity	(absence	from	work).	In	Italy,	according	to	the	recent	literature,	the	total	social	
cost	associated	with	RA	is	€3.5	billion	per	year	with	a	mean	of	€13.595	per	adult	patient.	In	
particular,	21%	of	the	total	costs	are	direct	costs	while	79%	are	indirect	costs.	These	costs	are	
in	line	with	the	other	European	countries	and	the	total	mean	annual	cost	is	estimated	at	about	
€25.1	 billion	 (Benucci	 et	 al.	 2016).	 RA	 is	 characterized	 by	 the	 chronic	 inflammation	 of	 the	
synovial	membrane,	which	leads	to	its	hyperplasia.	During	the	disease,	the	small	diarthrodial	
joints	of	hands	and	feet	are	affected	first	in	a	symmetric	manner	(Firestein	2003).	The	main	
clinical	symptoms	associated	with	RA	are	swelling	of	joints,	morning	stiffness	and	pain	due	to	
the	 progressive	 cartilage	 degradation	 and	 bone	 erosion.	 These	 symptoms	 together	 with	
radiological	data	and	the	serological	presence/absence	and	type	of	autoantibodies	are	needed	
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to	diagnose	the	disease,	its	degree	and	to	choose	the	right	treatment	strategy.	To	this	aim,	the	
American	 College	 of	 Rheumatology	 (ACR)	 and	 the	 European	 League	 Against	 Rheumatism	
(EULAR)	developed	classification	criteria	to	define	the	RA	severity	(Table	1).	According	to	these	
criteria,	which	provides	a	score	from	0	to	10,	the	score	of	³	6	its	indicative	of	the	presence	of	
definite	RA	(Aletaha	et	al.	2010).	
	 	
ACR/EULAR	2010	criteria	 SCORE	
1.	Joint	involvement	 	
• One	medium	to	large	joint	 0	
• Two	to	ten	medium	to	large	joints	 1	
• One	to	three	small	joints	(large	joints	not	counted)	 2	
• Four	to	ten	small	joints	(large	joints	not	counted)	 3	
• More	than	ten	joints	(at	least	one	small	joint)	 5	
2.	Serology	 	
• Negative	RF	and	negative	ACPA	 0	
• Low	positive	RF	or	low	positive	ACPA	 2	
• High	positive	RF	or	high	positive	ACPA	 3	
3.	Acute	phase	reactants	 	
• Normal	CRP	and	normal	ESP	 0	
• Abnormal	CRP	or	abnormal	ESP	 1	
4.	Duration	of	symptoms	 	
• Less	than	6	weeks	 0	
• 6	weeks	or	more	 1	
Table	1:	Classification	criteria	for	rheumatoid	arthritis	2010	ACR/EULAR.		
1.1.1. Aetiology		
The	leading	cause	of	rheumatoid	arthritis	is	still	unclear,	however	several	studies	suggest	that	
environmental	 factors	 and	 genetic	 predisposition	 increase	 the	 probability	 to	 develop	 RA	
(McInnes	&	Schett	2011a).	Usually,	patients	are	divided	 into	 seropositive	and	 seronegative	
regarding	 the	presence	or	absence	of	autoantibodies	 specific	 for	 citrullinated	autoantigens	
(antibodies	to	citrullinated	protein	antigens	(ACPAs))	and	autoantibodies	specific	for	self	IgG-
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Fc	(rheumatoid	factor	(RF)).	Two-thirds	of	the	patients	are	seropositive	and	show	worst	clinical	
symptoms	compared	to	seronegative	patients.	Moreover,	the	aetiology	for	the	seronegative	
is	 less	 well	 understood	 compared	 to	 the	 seropositive,	 probably	 because	 of	 a	 lack	 of	
homogeneous	 features	 (Malmström	et	al.	2016).	Despite	 the	 fact	 that	both	the	RF	and	the	
ACPAs	are	present	in	the	blood	before	the	first	symptoms	of	the	disease,	the	RF	is	less	specific	
(Aggarwal	et	al.	2009).	Indeed,	it	occurs	in	other	inflammatory	conditions,	while	the	ACPAs	are	
detected	in	less	than	2%	in	healthy	individuals	(Malmström	et	al.	2016).		
1.1.2. Genetics	
As	previously	mentioned,	genetic	factors	have	a	key	role	in	the	pathogenesis	of	RA.	Indeed,	
very	 interesting	 epidemiological	 studies,	 linking	 the	 genetic	 features	 to	 the	 pathology,	
demonstrated	 that	 native	 American-Indian	 populations	 have	 high	 occurrence	 of	 RA	 (5.3-
6.8%)(Del	Puente	et	al.	1989)(Harvey	et	al.	1981)	whereas	rural	African	populations	(Beighton	
et	al.	1975)(A.	J.	Silman	et	al.	1993)	and	some	populations	from	south-east	Asia(Dans	et	al.	
1997),	China(Zeng	et	al.	1997)	and	Japan(Shichikawa	et	al.	1999)	show	low	occurrence	(0.2-
0.3%).	 Other	 studies	 have	 proved	 a	 fourfold	 increased	 risk	 of	 RA	 in	 monozygotic	 twins	
compared	to	dizygotic	twins	(MacGregor	et	al.	2000)(A	J	Silman	et	al.	1993).	Moreover,	it	is	
known	that	a	positive	family	history	increases	the	risk	of	RA	from	three	to	five	times	(Smolen	
et	al.	2016).	Recently,	genome-wide	association	studies	have	identified	more	than	a	hundred	
loci	associated	with	rheumatoid	arthritis	(Consortium	2007)(Stahl	et	al.	2010).	Among	these	
loci,	the	major	histocompatibility	complex	(MHC)	class	II,	known	in	human	as	human	leucocyte	
antigen	(HLA)	class	II	and	responsible	for	the	antigen	presentation	to	T-helper	(Th)	cells,	was	
extensively	studied.	Particular	HLA	alleles	like	HLA-DR1	and	HLA-DR4	where	found	with	high	
frequencies	in	the	seropositive	patient	affected	by	RA	if	compared	with	healthy	individuals.	
These	alleles	share	a	common	aminoacid	sequence	(known	as	the	shared	epitope)	(Gregersen	
et	al.	1987)	 in	the	third	hypervariable	region	(called	pocket	4	(P4))	of	the	beta	chain	 in	the	
peptide	binding	groove.	Aminoacids	found	in	position	11,	71	and	74	(Raychaudhuri	et	al.	2012)	
confer	 a	positive	 charge	 to	 the	P4,	which	 is	not	 able	 to	 accommodate	peptides	 containing	
arginine	due	to	its	positive	charge	(Scally	et	al.	2013).	However,	when	an	arginine	is	converted	
in	a	neutral	citrulline	the	peptide	is	able	to	fit	in	the	P4	and	so	it	can	be	presented	to	the	T-
helper	cell	(Figure	1).	The	conversion	of	arginine	to	citrulline	is	performed	by	an	enzyme	called	
peptidyl	arginine	deaminase	(PAD).	Indeed,	it	has	been	demonstrated	that	PAD	is	overexpress	
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matter	of	fact,	patients	with	RA	have	higher	antibody	titre	for	P.	Gingivalis	which	correlates	
with	higher	concentration	of	C-reactive	protein	and	RA-associated	autoantibodies	(Mikuls	et	
al.	 2009).	 Moreover,	 this	 bacterium	 has	 its	 own	 PAD	 enzyme	 able	 to	 switch	 arginine	 in	
citrulline.	For	this	reason,	a	model	of	molecular	mimicry	has	been	hypothesized.	According	to	
this	model,	when	the	immune	system	reacts	against	P.	Gingivalis	infection,	antibodies	against	
its	 citrullinated	peptides	 are	produced	and,	due	 to	 the	high	 similarity,	 the	 immune	 system	
tolerance	is	compromised	inducing	the	epitope	spreading	to	self	citrullinated	proteins	leading	
to	a	strong	autoimmune	response	(Hajishengallis	2014)(Wegner	et	al.	2010).	Other	infectious	
agents	like	Epstein-Barr	virus	and	Escherichia	coli	are	known	to	trigger	RA	by	molecular	mimicry	
and,	recently,	gut	microbiome	has	been	studied	for	its	role	for	the	priming	and	progression	of	
the	disease.	
1.1.4. Epigenetics	
Epigenetic	processes	are	heritable	changes	in	the	gene	expression	without	modification	in	the	
DNA	sequence.	This	is	possible	due	to	DNA	methylation	or	histones	and	chromatin	associated	
proteins	 post-translational	 modifications	 such	 as	 acetylation,	 methylation	 and	
phosphorylation.	 These	 processes	 lead	 to	 a	 very	 complex	 network	where	 genes	 are	 finely	
regulated	 throw	 their	 activation	 or	 silencing.	 Epigenetic	 contributions	 to	 the	 onset	 and	
progression	of	RA	have	been	recently	highlighted.	Indeed,	ten	different	methylated	positions	
were	identified	as	responsible	to	increase	the	risk	to	develop	RA	(Liu	et	al.	2013).	Moreover,	it	
was	demonstrated	that	knee	and	hip	RA	fibroblast-like	synoviocytes	(FLS)	show	different	DNA	
methylation	 signature	 of	 genes	 encoding	 the	 JACK-STAT	 pathway,	 explaining,	 partly,	 the	
different	 degree	 of	 inflammation	 between	 joints	 (Ai	 et	 al.	 2016).	 Another	 mechanism	 of	
epigenetic	regulation	is	represented	by	many	microRNAs.	They	can	target	mRNAs	leading	to	
an	 additional	 regulation	 of	 different	 genes	 in	 different	 cells	 type	 such	 as	 lymphocytes,	
macrophages	and	FLS	(Blüml	et	al.	2011).		
1.1.5. Pathophysiology	
As	already	mentioned	above,	the	cause	of	the	disease	is	still	unclear.	What	we	know	is	that	
environmental	 factors,	 a	 characteristic	 genotype,	 post-translational	modification	 and	other	
kinds	of	gene	expression	regulations	contribute	to	the	onset	of	the	disease.	According	to	one	
of	 the	 latest	 review	 published	 on	 Nature	 Review	 Rheumatology	 by	 V.	 Malmstrom	 et	 al.	
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(Malmström	 et	 al.	 2016)	 during	 the	 development	 of	 the	 pathology,	 there	 are	 four	 phases	
(Figure	2).	The	first	phase	is	called	"triggering".	At	this	stage,	the	mucosal	surfaces,	such	as	the	
lining	 of	 the	 lungs,	 gums	 and	 intestinal	 mucosa,	 together	 with	 environmental	 stimuli	 and	
genetic	risk	factors	trigger	the	immune	response	against	self-peptides.	In	the	second	phase,	
called	 “maturation”,	 the	 immune	 system	matures	 and	 spreads	 its	 epitopes,	 enhancing	 the	
antibody	titre	of	RF	and	ACPA.	This	 immune	response	does	not	occur	 in	 the	 joints	but	 into	
lymph	 nodes	 and/or	 into	 other	 secondary	 lymphoid	 tissue	 where	 T-cells	 and	 B-cells	 are	
activated	and	proliferate.	The	third	phase	called	“targeting”	is	characterized	by	the	presence	
of	 the	 clinical	 signs,	 such	as	bone	 loss	and	 joint	pain.	 Specifically,	ACPAs	may	directly	bind	
osteoclasts,	which	 in	 response	produce	C-X-C	Motif	Chemokine	Ligand	8	 (CXCL8)	known	as	
interleukin	8	(IL8).	It	can	acts	as	growth	factor	for	osteoclasts	or	as	pain	inducer	when	it	binds	
their	 receptors,	 C-X-C	 Motif	 Chemokine	 receptor	 1	 (CXCR1)	 and	 CXCR2,	 expressed	 on	
nociceptive	nerves.	The	last	phase,	called	“fulminant	disease”,	is	characterized	by	the	synovitis.	
Indeed,	 ACPAs	 can	 bind	 citrullinated	 histones	 causing	 the	 neutrophil	 extracellular	 traps	
(NETosis).	Moreover,	other	citrullinated	proteins	can	be	bound	by	Toll-like	receptors	 (TRLs)	
expressed	on	synovial	cells	and	APCs,	which	in	turn	produce	pro-inflammatory	cytokines	like	
tumor	 necrosis	 factor	 (TNF),	 interleukin-6	 (IL-6)	 and	 matrix	 metalloproteinases	 (MMPs),	
responsible	 for	 the	 cartilage	 and	 bone	 destruction.	 According	 to	 this	 model,	 the	 immune	
system	 is	 first	activated	 in	a	different	 tissue	by	a	 local	 inflammation	and	then	this	 immune	
response	target	the	joints,	developing	an	inflammation	cascade	leading	to	an	established	RA.		
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1.1.6. Local	inflammation	
Following	this	model	of	pathogenesis,	the	possible	first	local	inflammation	may	occur	in	the	
lung	mucosa.	Several	findings	support	this	model.	Among	these,	it	has	been	shown	that	patient	
with	 early	 ACPA-positive	 RA	 presented	 macroscopic	 and	 microscopic	 changes,	 such	 as	
inflammatory	 cells	 infiltration,	 of	 the	 lung	mucosa,	 whereas	 seronegative	 RA	 patients	 and	
healthy	 individuals	 do	 not	 show	 any	 changes	 (Reynisdottir	 et	 al.	 2014).	 Another	work	 has	
demonstrated	 that	 bronchus-associated	 lymphoid	 tissue	 (BALT),	 described	 as	 a	 mucosal	
lymphoid	organ,	were	mainly	found	in	RA	patients	compared	with	healthy.	Interestingly	they	
correlate	with	an	increased	tissue	damage,	suggesting	an	important	role	in	the	pathogenesis	
due	to	the	overexpression	of	PAD2	and	the	production	of	chemokines	and	cytokines	(Rangel-
Moreno	et	al.	2006).	Moreover,	it	is	known	that	smoke	and	other	noxious	agents	increase	the	
expression	of	PADs,	which	correlate	with	an	increased	amount	of	citrullinated	proteins,	in	the	
bronchial	tissue	of	patients	with	RA	(Makrygiannakis	et	al.	2008).	All	these	evidence	suggest	
that	 antigen	 presenting	 cells	 (APCs),	 like	 dendritic	 cells,	 macrophages	 and	 B-cells,	 locally	
activated	by	neo-citrullinated	antigens	may	trigger	T-cell	mediated	immunity	(Figure	3).	
However,	since	not	all	seropositive	patients	with	RA	present	inflammation	or	changes	in	the	
lung	mucosa,	 possibly	 other	 tissues	 are	 able	 to	 trigger	 the	 first	 immune	 response.	 Among	
them,	 the	most	 accredited	 are	 the	 gums,	 probably	 because	 of	 the	 peridontitis	 caused	 by	
phorphiromonas	gingivalis,	and	the	intestinal	tract	due	to	changes	in	the	gut	microbiota.		
It	is	evident	that	RA	is	a	clinical	condition	characterized	by	a	complex	crosstalk	between	the	
adaptive	and	the	innate	parts	of	the	immune	system.	In	particular,	the	complement	system	
has	an	important	role	in	this	pathology	(Trouw	et	al.	2017).	Indeed,	complement	proteins	C3	
and	C4	have	been	shown	to	decrease	in	joints	of	RA	patients	because	of	consumption	(Swaak	
et	al.	1987),	while	complement	activation	fragments,	such	as	the	membrane	attack	complex	
sC5b-9	and	the	cleavage	 fragments	Bb,	were	 increased	several	 times	 (Brodeur	et	al.	1991).	
ACPA	and	RF	may	interact	with	antigens	present	in	the	joints	forming	immune	complexes	able	
to	activate	the	local	complement	(Suwannalai	et	al.	2014).	Other	molecules,	released	from	the	
extracellular	matrix	 of	 cartilage	 or	materials	 from	 dead	 cells,	 can	 trigger	 the	 complement	
activation	thus	suggesting	that	the	complement	system	has	a	role	in	both	early	phase	and	late	
phase	 of	 the	 disease	 (Sjöberg	 et	 al.	 2005).	 It	 was	 demonstrated	 that	 both	 classical	 and	
alternative	pathways	are	involved	in	the	complement	activation,	but	only	the	alternative	was	
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chemokines	and	growth	factors.	All	these	factors	are	able	to	activate	FLS	and	B-cell,	which	in	
turn	produce	IL-6	and	matrix	metalloproteinases	(MMPs).	Thus,	the	positive	feedback	 loop,	
generated	 by	 the	 paracrine/autocrine	 effects	 of	 these	 factors,	 leads	 to	 a	 perpetual	
inflammation.	Indeed,	the	inflamed	hyperplastic	synovial	tissue	at	the	cartilage-bone	interface,	
called	 pannus,	 behaves	 like	 a	 locally	 invasive	 tumor,	 where	 activated	 FLS,	 macrophages,	
osteoclasts	and	lymphocytes	are	able	to	destroy	and	infiltrate	the	lining	layer	and	the	cartilage	
(Bartok	 &	 Firestein	 2011).	 The	 FLS	 proliferation	 is	 stimulated	 by	 growth	 factors	 like	 basic	
fibroblast	growth	 factor	 (bFGF)	 (Melnyk	et	al.	1990),	platelet-derived	growth	 factor	 (PDGF)	
(Mor	et	al.	2005)	and	transforming	growth	factor-beta	(TGF-beta)	(Allen	et	al.	1990),	released	
by	 leukocytes.	 Moreover,	 the	 FLS	 apoptosis	 rate	 is	 decreased,	 probably	 because	 of	 p53	
mutation	(Firestein	et	al.	1997),	B-cell	lymphoma	2	(Bcl-2)	overexpression	(Perlman	et	al.	2000)	
or	Fas	ligand	(FasL)	dysregulation	(Perlman	et	al.	2001).	The	FLS	have	a	primary	role	in	cartilage	
invasion	 and	 degradation,	 indeed	 they	 secrete	 a	 broad	 set	 of	 MMPs	 responsible	 for	 this	
process.	In	particular,	during	the	disease,	FLS	stimulated	with	IL-1,	TNF-beta	and	growth	factors	
overexpress	 MMP1,	 MMP3,	 MMP10	 (Tolboom	 et	 al.	 2002),	 MMP8,	 MMP9,	 MMP11	 and	
MMP13	(Mor	et	al.	2005).	These	enzymes	are	responsible	for	the	collagen	I	and	II	degradation,	
leading	to	the	cartilage	destruction,	increasing	the	space	between	joints.	It	was	demonstrated	
that	FLS	produce	IL-6,	promoting	Th17	differentiation	and	proliferation	(Lin	et	al.	2012).	FLS	
feed	the	inflammatory	process	contributing	to	the	formation	of	new	vessels,	indeed	numerous	
pro-angiogenetic	 factors	 are	 produced.	 Among	 these,	 vascular	 endothelial	 growth	 factor	
(VEGF)	 (Cho	 et	 al.	 2002),	 fibroblast	 growth	 factor-2	 (FGF-2)	 (Yamashita	 et	 al.	 2002)	 and	
interleukin-18	(IL-18)	(Morel	et	al.	2002)	contribute	to	the	inflammatory	process	and	pannus	
formation	due	 to	 the	new	vessels	growth.	However,	 the	 formation	of	new	vessels	and	 the	
production	of	MMP	are	not	solely	responsible	for	the	progression	of	cartilage	inflammation	
and	destruction,	since	fibroblasts	can	directly	interact	with	T-cells,	B-cells,	and	osteoclasts.	The	
latter	is	the	primary	responsible	for	the	destruction	and	deformation	of	the	bones	due	to	their	
acid	enzymatic	machinery	(able	to	destroy	mineralized	cartilage	and	bones).	Lesions	of	bones	
and	cartilage	are	progressively	invaded	by	leukocytes,	which	in	the	end	reach	the	bone	marrow	
increasing	the	inflammatory	process	(Jimenez-Boj	et	al.	2005).	It	is	known	that	macrophages	
colony-stimulating	 factor	 (M-CSF)	 and	 the	 receptor	 activator	 of	 NF-κB	 ligand	 (RANKL)	 are	
principally	responsible	for	the	osteoclasts	survival,	activation	and	differentiation	(Glantschnig	
et	 al.	 2003).	 However,	 TNF-a,	 IL-1,	 IL-6	 and	 IL-17	 play	 a	 central	 role	 in	 the	 activation	 and	
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differentiation	of	osteoclasts	(Schett	&	Teitelbaum	2009).	Indeed,	treatments	able	to	target	
these	 cytokines	 were	 effective	 for	 the	 prevention	 of	 bone	 destruction	 (McInnes	 &	 Schett	
2011).		
1.1.8. Adaptive	immunity	
It	 is	 known	 that	 adaptive	 immunity	 has	 a	 pivotal	 role	 in	 the	 pathogenesis	 of	 rheumatoid	
arthritis.	 In	 particular,	 T-cells	 (CD4+)	 are	 activated	 through	 the	 interaction	 with	 antigenic	
peptide	 fragment	 presented	 by	 HLA	 class	 II	 expressed	 by	 professionals	 APC.	 Recently,	
enormous	attention	has	been	focused	on	type	17	helper	T-cell	(Th17).	This	particular	subset	of	
T	helper	cells	has	pro-inflammatory	phenotype	that	produces	TNF-a	and	interleukin	17A,	17F,	
IL-21	and	IL-22	(Miossec	et	al.	2009).	The	synovial	fluid	of	RA	patients	contains	many	cytokines	
that	promote	the	differentiation	of	Th17	and	simultaneously	suppress	the	differentiation	of	
regulatory	helper	T-cell	(Treg).	This	process	breaks	homeostasis	in	favor	of	a	pro-inflammatory	
process	by	creating	an	imbalance	between	pro-inflammatory	cytokines,	chemokines,	adhesion	
proteins	and	growth	factors.	Indeed,	it	was	demonstrated	that	this	equilibrium	can	be	restored	
by	TNF-a	inhibitors	proving	the	key	role	of	TNF-a	in	the	inflammatory	process	(Nadkarni	et	al.	
2007).	Moreover,	TNF-a	and	IL-17A	are	able	to	activate	fibroblasts	and	chondrocytes,	fueling	
the	inflammatory	process	(Zupan	et	al.	2013)(Mundy	2007).	B-cells,	together	with	T-cells,	have	
a	central	role	in	the	pathogenesis,	mainly	producing	IgG	ACPA.	In	the	synovial	tissue,	B-cells	
are	often	aggregated	to	T-cells,	forming	the	so	called	ectopic	(or	tertiary)	 lymphoid	follicles	
(Jing	&	Choi	2016)(Timmer	et	al.	2007).	This	structure	promotes	B-cell	survival	and	proliferation	
through	 the	 expression	 of	 a	 proliferation-inducing	 ligand	 (APRIL),	 B-lymphocyte	 stimulator	
(BLyS)	and	several	different	chemokines	(Seyler	et	al.	2005).		
1.1.9. Innate	immunity	
As	already	described	in	the	paragraph	“local	inflammation”,	the	complement	system,	which	is	
part	of	the	innate	immune	system,	has	an	important	role	in	the	development	of	RA.	Moreover,	
cells	of	the	innate	immune	system	contribute	to	the	synovial	membrane	inflammation	because	
of	the	mast	cells,	macrophages	and	natural	killer	cells	infiltration.	Neutrophils	also	participate	
in	the	synovitis	but	are	mainly	located	in	the	synovial	liquid.	Among	these	cells,	Macrophages	
are	considered	the	main	actors	because	of	their	cytokines	production.	Indeed,	they	secrete	a	
great	 cytokine	 portfolio	 such	 as	 TNF-alpha,	 IL-1,	 IL-6,	 IL-12.	 Moreover,	 they	 release	
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chemokines,	leukotrienes,	prostaglandins,	and	complement	proteins.	All	these	molecules	have	
the	possibility	to	increase	the	vascular	permeability,	which	in	turn	increase	cell	extravasation	
(Duque	&	Descoteaux	2014).	Usually,	Macrophages	are	activated	by	toll	like	receptors	(TLR)	
and	 nucleotide-binding	 oligomerization	 domain	 (NOD)	 like	 receptors	 (NLRs).	 In	 addition,	
macrophages	can	be	activated	by	cytokines,	immune	complexes	and	lipoproteins	(McInnes	&	
Schett	2011b).	Macrophages	maturation	and	synovial	infiltration	are	promoted	by	M-CSF,	G-
CSF	and	granulocytes-macrophages	colony-stimulating	factor	(MG-CSF)	which	enhance	their	
migration	 from	 the	 bone	marrow	 to	 the	 inflamed	 tissue	 (Cornish	 et	 al.	 2009).	Mast	 cells,	
activated	by	TLR,	Fc	receptors	g	or	Fc	receptors	e	produce	cytokines,	chemokines,	proteases	
and	 vasoactive	 amines	 while	 Neutrophils	 produce	 prostaglandins,	 reactive	 oxygen	
intermediates	and	proteases	(Cascão	et	al.	2010).		
1.2. Neoangiogenesis	
The	formation	of	new	capillaries	from	pre-existing	vessels	is	a	process	called	neoangiogenesis.	
This	is	a	complex	and	well-orchestrated	process	which	involves	many	cell	types	and	mediators.	
It	occurs	in	physiological	conditions	during	organ	development,	growth	and	tissue	remodeling	
due	to	the	reorganization	of	the	blood	vessels	(Konisti	et	al.	2013).	The	vessels	have	an	inner	
layer	 formed	 by	 endothelial	 cells	 with	 a	 surrounding	 basal	 lamina,	 pericytes	 and	 smooth	
muscles	cells	(Bergers	2005).	It	has	been	demonstrated	that	precursors	of	endothelial	cells	are	
CD34+	cells,	which	express	the	vascular	endothelium	growth	factor	(VEGF)	receptor	2.	These	
cells	express	also	the	CXCR4	and	migrate	in	response	to	stromal-derived	factor	(SDF)-1	or	VEGF.	
(Peichev	et	al.	2000)(Asahara	1997).	Several	factors	such	as	cytokines,	chemokines,	molecules	
for	cell	adhesion	and	growth	factors	stimulate	the	migration	and	activation	of	these	cells.	Once	
these	cells	are	activated,	they	start	to	disrupt	the	underlying	basal	membrane	 invading	the	
extracellular	matrix.	These	proliferating	cells	follow	the	VEGF	gradient	to	reach	the	tissue	of	
interest	where	they	organized	the	 lumen	and	the	final	shape	of	the	vessel	with	the	help	of	
pericytes	attracted	due	to	the	secretion	of	the	endothelial	cell	PDGFb	(Bergers	2005).		
Neoangiogenesis,	 as	 already	 mentioned,	 is	 a	 physiological	 process,	 however	 it	 plays	 an	
important	 role	 in	 several	 pathological	 processes.	 Usually,	 damaged	 tissues	 face	 hypoxic	
conditions	 which,	 in	 turn,	 promotes	 the	 formation	 of	 new	 vessels	 in	 order	 to	 restore	 the	
regular	 blood	 supply	 and	 therefore	 a	 suitable	 amount	 of	 oxygen.	 The	 hypoxia	 is	 a	 shared	
condition	of	many	different	pathologies	like	autoimmune	and	cancer	diseases.	In	RA,	during	
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the	chronic	inflammation	of	the	synovial	tissue,	synovial	fibroblasts	acquire	a	high	proliferative	
phenotype,	moreover,	due	to	the	huge	 leukocytes	 infiltration,	there	 is	an	 increased	oxygen	
consumption.	Different	studies	have	demonstrated	that	VEGF,	pro-inflammatory	cytokines	like	
IL-6	 and	 matrix	 metalloproteinases	 expression	 (MMP1	 and	 MMP3)	 are	 associated	 to	 the	
hypoxia	inducible	factors	(HIF)	activation	(Lu	&	Kang	2010)(Ahn	et	al.	2008).	Therefore,	hypoxia	
not	 only	 plays	 a	 fundamental	 role	 in	 the	 formation	 of	 new	 vessels	 but	 contributes	 to	 the	
degradation	of	cartilage	by	the	expression	of	metalloproteases.	The	RA	synovial	membrane,	
infiltrated	by	leukocytes,	expresses	pro-inflammatory	cytokines	such	as	IL-1,	IL-6,	TNF-alpha	
and	transforming	growth	factor	beta	(TGFb)	which	are	able	to	increase	the	expression	of	VEGF	
(Marrelli	et	al.	2011).	Chemokines	e	chemokines	receptors	contribute	to	the	formation	of	new	
vessels	which	 promotes	 inflammation	 of	 the	 synovial	membrane.	 One	 of	 the	most	 potent	
chemokines	 is	 the	 CXCL12,	 also	 called	 stromal	 cell-derived,	 which	 is	 overexpressed	 in	
inflammatory	disease.	Its	receptor	CXCR4	is	expressed	by	hemopoietic	stem	cells,	monocytes	
and	lymphocytes	and	exerts	a	homing	function.	CXCL12-CXCR4	system	is	strongly	implicated	
in	 the	 neoangiogenesis.	 It	was	 demonstrated	 that	 CXCL12	 induces	 autocrine	 expression	 of	
VEGF	promoting	the	neoangiogenesis;	in	addition,	CXCR4	knockout	mice	exhibit	a	decreased	
vascularization	(Pablos	et	al.	2003).	Although	chemokines	are	responsible	 for	the	 leukocyte	
homing	in	the	inflamed	synovial	tissue,	the	expression	of	cellular	adhesion	molecules	(CAMs)	
expressed	by	endothelial	cells	play	a	crucial	role	in	leukocyte	adhesion	and	transendothelial	
migration.	At	the	beginning,	leukocyte	tethering	and	rolling	are	mediated	by	E-selectins	and	P-
selectins	while	the	firm	adhesion	is	mediated	by	intercellular	adhesion	molecule-1	(ICAM-1)	
and	 vascular	 cell	 adhesion	molecule-1	 (VCAM-1)	 able	 to	 bind	b2	 integrin	 and	a4b2	 integrin	
respectively	(Szekanecz	&	Koch	2008).	Of	extreme	interest	is	the	integrin	avb3	which	is	involved	
in	neoangiogenesis	and	have	been	found	to	be	overexpressed	in	damaged	tissue	(Szekanecz	
et	al.	2009).	Its	relevance	was	also	demonstrated	in	animal	models	of	RA,	where	the	blocking	
of	 the	 avb3	 reduced	 neoangiogenesis,	 cell	 infiltration,	 pannus	 formation	 and	 cartilage	
degradation	 (Storgard	et	 al.	 1999).	 For	 these	 reasons,	 in	order	 to	 reduce	neoangiogenesis,	
drugs	able	to	block	this	integrin	were	developed	but	they	were	ineffective	in	human	clinical	
trials	(Lainer-Carr	&	Brahn	2007).	Although,	due	to	its	overexpression	in	blood	vessels	of	tumor	
endothelial	 cells	 or	 in	 inflamed	 kidney	 tissue,	 peptides	 containing	 aminoacids	 	Arg-Gly-Asp	
(RGD),	able	to	bind	the	avb3,	have	been	used	to	deliver	anticancer	or	anti-inflammatory	drugs	
directly	in	the	tissue	of	interest	(Danhier,	Breton,	et	al.	2012)(Durigutto	et	al.	2017).		
Introduction	
	
	 	 16	
1.3. Animal	models	of	rheumatoid	arthritis	
Several	experimental	animal	models	of	rheumatoid	arthritis	have	been	developed	in	order	to	
understand	etiology	and	pathogenic	mechanisms	of	this	autoimmune	disease.	Today,	these	
models	are	 important	to	test	new	therapeutics,	study	their	pharmacokinetics,	effectiveness	
and	side	effects	(Asquith	et	al.	2009).	Despite	the	progress	made	to	develop	animal	models	of	
arthritis,	 each	model	 shows	peculiar	 features.	 Indeed,	 the	model	 to	 use	 should	 be	 chosen	
according	 to	 the	aim	of	 the	 research	 taking	 into	account	 its	 pros	 and	 cons.	Moreover,	 the	
results	 obtained	with	 animal	models	 should	 be	 assessed	 carefully	 because	 of	 the	 intrinsic	
differences	between	human	and	other	animals	(Hu	et	al.	2013).	
1.3.1. Collagen	induced	arthritis	(CIA)	
The	 discovery	 of	 anti-collagen	 antibodies,	 that	 have	 been	 found	 in	 the	 serum	 of	 patients	
affected	by	rheumatoid	arthritis,	was	the	motivation	to	develop	an	experimental	model	based	
on	 type	 II	 collagen.	 It	became	the	best	model	 to	 test	new	therapeutics,	 such	as	biologicals	
DMARDs,	and	to	understand	pathogenic	mechanisms	of	the	disease.	The	reason	of	the	success	
lies	in	the	fact	that	it	shares	several	aspects	of	the	human	disease.	Indeed,	the	onset	of	CIA	is	
mainly	dependent	on	T-cells	and	B-cells	with	a	huge	immune	response	against	collagen	type	II,	
which	is	one	of	the	main	components	of	the	cartilage	(Brand	et	al.	2007).	This	experimental	
method	based	on	the	intradermal	injection	of	type	II	collagen	was	described	for	the	first	time	
in	1977	by	Trentham	et	al.	(Trentham	et	al.	1977).	Thanks	to	this	animal	model,	the	role	of	T	
lymphocytes,	in	particular	helper	T-cells,	has	been	clarified,	indeed	has	been	shown	that	they	
are	essential	for	the	onset	and	progression	of	RA	(Klareskog	et	al.	1983).	The	model	develops	
a	polyarthritis,	where	each	mouse	can	show	a	different	number	of	joints	involved	and	different	
degree	of	inflammation	for	each	joint.	It	is	characterized	by	a	synovial	hyperplasia,	cartilage	
and	bone	degradation	associated	to	a	synovial	membrane	leukocyte	infiltration	(Trentham	et	
al.	1977).	DBA/1	(H-2q)	is	the	mouse	strain	associated	with	the	highest	percentage	of	disease	
incidence	(80-90%),	although	several	transgenic	HLA-DR	mouse	strain	has	been	generated	in	
order	to	study	specific	HLA	susceptibility	and	involvement	in	the	pathogenesis.	For	example,	
humanized	HLA-DR4-transgenic	mice	were	generated	to	understand	the	higher	RA	incidence	
in	female	(Taneja	et	al.	2007).	Moreover,	it	has	been	demonstrated	that	arthritic	synovium	of	
CIA	mouse	 is	 characterized	 by	 an	 active	 angiogenesis	 suggesting	 that	 VEGF/VEGF	 receptor	
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pathway	could	be	a	potential	therapeutic	target	(Raatz	et	al.	2012).	Furthermore,	it	has	been	
found	that	complement	system	inhibition	plays	a	role	in	CIA	model,	reducing	the	progression	
and	the	onset	of	the	disease	(Linton	&	Morgan	1999).	
1.3.2. Antigen-induced	arthritis	(AIA)	
The	antigen	induced	arthritis	model	is	an	experimental	procedure	to	develop	monoarthritis.	
First,	 animals	are	 immunized	with	 two	 intra-dermal	 injections	of	methylated	bovine	 serum	
albumin	(mBSA)	or	another	antigen,	inducing	an	immune	response	against	the	protein	with	a	
production	of	 anti-antigen	 antibodies.	 Then,	 the	 same	antigen	 is	 injected	 into	 a	 knee	 joint	
cavity	 inducing	 the	 formation	 of	 immune	 complexes	 and	 consequently	 the	 inflammation	
(Griffiths	1992).	Three	days	after,	the	inflammation	is	evident	due	to	the	swollen	knee	joint.	
The	 inflammatory	 process	 reaches	 the	 highest	 degree	 after	 one	 week,	 when	 synovial	
hyperplasia,	 erosion	 of	 cartilage	 and	 bone	 are	 evident	 by	 histological	 analysis.	 The	 tissue	
damage	is	caused	by	both	innate	and	adaptive	immunity.	It	was	demonstrated	that	purified	
helper	T	cells,	previously	sensitized	for	mBSA	and	injected	directly	into	the	joint	together	with	
the	antigen	were	able	to	induce	the	inflammation	into	not	immunized	animals	(Klasen	et	al.	
1986).	In	addition,	the	complement	system	has	a	leading	role	in	this	model,	indeed	have	been	
studied	that	animal	with	AIA,	if	treated	with	anti-C5	antibodies	or	C5a	antagonist	showed	a	
decreased	joint	swelling	and	a	lower	histopathological	score	(Woodruff	et	al.	2002).	Moreover,	
inflamed	synovial	 tissues	of	 the	animal	with	AIA	have	been	associated	with	a	higher	vessel	
density	 proving	 the	 fundamental	 role	 of	 the	 neoangiogenesis	 in	 this	 model.	 Indeed,	 the	
knockout	of	the	gene	VEGFB,	a	growth	factor	that	belongs	to	the	vascular	endothelial	growth	
factor	family,	reduced	the	synovial	inflammation	and	the	vascular	density	(Mould	et	al.	2003).	
This	model	was	extensively	used	to	study	pathogenic	mechanisms,	but	it	has	been	overcome	
by	the	CIA	model	because	of	the	reason	described	in	the	previous	paragraph.	Although	AIA	is	
considered	obsolete	to	investigate	pathogenic	mechanism,	this	model	is	still	excellent,	at	least	
in	 the	 first	 step,	 to	 study	 the	biodistribution	of	 new	 classes	 of	 therapeutics	which	 aims	 to	
specifically	target	the	inflamed	synovial	tissue	(Macor	et	al.	2012)(Durigutto	et	al.	2017).	
1.3.3. Other	models	of	RA	
Other	rheumatoid	arthritis	models	have	been	developed	over	the	years.	Among	these,	one	of	
the	first	models	of	rheumatoid	arthritis	is	based	on	Freund’s	adjuvant	and	for	this	reason	it	is	
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called	 “adjuvant	 induced	 arthritis”.	 Freund’s	 adjuvant	 is	 a	mix	 of	mineral	 oil	 and	 antigens,	
which	acts	as	a	booster	of	the	immune	response.	This	model	has	been	used	to	investigate	the	
role	 of	 T-cells,	 which	 are	 stimulated	 by	 the	 adjuvant	 injection	 to	 start	 the	 inflammatory	
process.	 The	 rat	 strain	 is	 important	 for	 the	development	of	 inflammation,	 indeed	 Lewis	or	
Sprague-Dawley	strains	are	considered	susceptible	 strains	 showing	35%	of	 incidence,	while	
Buffalo	and	other	strains	are	considered	resistant	strains	showing	10%	of	incidence.	After	10-
15	days,	the	induced	arthritis	becomes	stable	for	2-3	weeks.	After	a	month	the	symptoms	are	
reduced.	The	adjuvant-induced	arthritis	by	Freund’s	complete	adjuvant	is	characterized	by	the	
ankyloses,	which	causes	the	partial	or	complete	stiffness	of	the	joint	 in	50%	of	the	affected	
animals.	Moreover,	cartilage	and	bone	erosions	are	usually	observed	 in	animals	developing	
the	inflammation	(Pearson	1956).	Although	this	model	is	simple	to	develop	and	it	requires	a	
short	time,	on	the	other	side	it	is	important	to	note	that	this	model	does	not	fully	reflect	the	
complexity	 of	 the	 disease	 and	 it	 is	 not	 suitable	 for	 long-term	 studies.	 Another	 model	 to	
mention	is	the	collagen	antibody-induced	arthritis	(CAIA).	This	model	is	similar	to	CIA,	and	is	
often	 used	 to	 test	 new	 therapeutics.	 It	 is	 induced	 by	 the	 administration	 of	 a	 cocktail	 of	
antibodies	against	collagen.	The	advantage	of	this	model	lies	in	its	speed	of	action	and	it	can	
be	used	for	several	strains	of	mice,	even	in	genetically	modified	mice.	However,	the	model	is	
expensive	and	very	fast	and	aggressive	compared	to	CIA,	therefore	it	is	less	suitable	to	study	
chronic	aspect	of	the	disease	(Khachigian	2006).	
1.4. Treatment	of	rheumatoid	arthritis	
The	 comprehension	 of	 new	 molecular	 mechanisms	 underlies	 rheumatoid	 arthritis	 has	
improved	the	diagnosis	and	therapy	of	the	disease.	Surely,	an	early	diagnosis	is	essential	for	a	
successful	 therapy.	 Indeed,	 treat	 the	 disease	 as	 early	 as	 possible	 allows	 avoiding	 cartilage	
degradation	 and	 bone	 remodelling	 which	 lead	 to	 a	 disability	 condition	 (Isaacs	 2010).	 As	
discussed	in	paragraph	1.1,	new	classification	criteria	for	rheumatoid	arthritis	were	presented	
in	2010.	These	reduced	the	shortcoming	of	the	previous	criteria	by	increasing	the	sensitivity	of	
21%	(Radner	et	al.	2014).	Then,	in	order	to	understand	whether	the	treatment	is	effective	or	
not,	two	different	systems	to	evaluate	the	disease-activity	have	been	developed.	The	American	
College	 of	 Rheumatology	 (ACR)	 improvement	 criteria	 assesses,	 in	 percentage,	 the	 relative	
efficacy	of	the	treatment	compared	to	another	therapy	or	placebo.	The	ACR20,	which	reflect	
the	20%	of	improvement,	compared	to	the	baseline,	is	considered	as	minimal	response,	while	
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the	ACR50	(50%)	is	a	moderate	response	and	the	ACR70	(70%)	is	the	major	response.	The	ACR	
criteria	are	widely	used	in	clinical	trials.	By	contrast,	the	disease	activity	score	(DAS),	using	28	
joints	(DAS28),	is	useful	for	daily	practice.	Indeed,	it	takes	into	account	different	parameters	
like	tender	and/or	swollen	joint	count,	global	health,	erythrocyte	sedimentation	rate	or	the	C-
reactive	protein	concentration.	With	a	special	equation,	the	DAS28	is	calculated	as	a	number	
which	reflects	the	activity	disease:	high,	moderate,	 low	and	remission	(Smolen	et	al.	2016).	
However,	these	systems,	able	to	evaluate	the	disease	activity,	are	useful	for	the	follow-up	of	
patients	with	RA,	but	it	is	important	to	evaluate	the	structural	damage	of	cartilage	and	bone.	
For	this	reason,	radiographic	images,	MRI	scans	and	ultrasound	analysis	are	often	performed	
to	highlight	joint	narrowing	space,	cartilage	and	bone	erosion	(Bugatti	et	al.	2012).	
The	treatment	of	RA	has	changed	over	the	last	thirty	years	improving	quality	of	life	of	affected	
patients.	This	was	possible	because	of	the	introduction	of	a	new	class	of	drugs	called	disease-
modifying	antirheumatic	drugs	 (DMARDs).	 Indeed,	drugs	belonging	 to	 this	class	are	able	 to	
reduce	 structural	 damage	 while	 non-steroidal	 anti-inflammatory	 drugs	 (NSAIDs)	 do	 not	
interfere	with	the	joint	damage.	However,	these	are	used	to	reduce	joint	pain	and	stiffness.	By	
contrast,	glucocorticoids	act	 like	DMARDs,	 reducing	disease	progression	 in	a	 rapid	manner,	
however	several	important	side	effects	were	associated	with	their	long	term	use.	DMARDs	are	
divided	into	two	categories:	synthetic	DMARDs	and	biological	DMARDs	(bDMARDs),	also	called	
biological	response	modifier	(BRM)	(van	Vollenhoven	2009).	
1.4.1. Synthetic	DMARDs	and	glucocorticoids	
Among	synthetic	DMARDs,	leflunomide,	sulfasalazine,	hydroxychloroquine	and	methotrexate	
are	 extensively	 used	 to	 treat	 RA	 and	 according	 to	 EULAR	 recommendation	 the	 treatment	
should	start	with	one	of	these	drugs	in	combination	with	low	dose	of	glucocorticoids.	However,	
methotrexate	is	considered	the	anchor	drug	because	it	shows	a	superior	outcome	compared	
with	other	DMARDs	and	because	 it	 has	been	demonstrated	 that	methotrexate	has	 a	 safer	
profile	that	other	synthetic	DMARDs,	probably	because	of	its	low	dose	of	administration.		
1.4.2. Methotrexate	
	Methotrexate	 (MTX)	 is	 a	 chemical	 compound	 analog	 to	 folic	 acid	 capable	 to	 inhibit	 the	
dihydrofolate	 reductase	 (DHFR),	 an	 enzyme	 essential	 for	 the	 synthesis	 of	 tetrahydrofolate	
(THF).	 THF	 is	 a	 cofactor	 involved	 in	 nucleic	 acids	 synthesis,	 highly	 required	 during	 cell	
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proliferation.	It	has	been	widely	used	as	a	chemotherapeutic	agent	to	treat	neoplastic	disease	
and	in	the	mid-1980s	it	was	introduced	at	low	doses	for	the	treatment	of	rheumatoid	arthritis.	
Initially,	 the	 therapeutic	 effect	 of	MTX	 on	 rheumatoid	 arthritis	was	 attributed	 solely	 to	 its	
ability	 to	 reduce	 the	 number	 of	 high	 proliferative	 cells,	 such	 as	 lymphocytes	 and	 other	
inflammatory	cells	responsible	for	the	inflammation.	Other	mechanisms	of	action	have	been	
recently	 demonstrated.	 Among	 them,	 the	 most	 accredited	 is	 that	 MTX	 inhibits	 5-
aminoimidazole-4-carbox-amide	ribonucleotide	(AICAR)	transformylase	increasing	the	AICAR	
levels,	thus	leading	to	the	release	of	intracellular	adenine	and	adenosine	into	the	extracellular	
space.	Subsequently,	extracellular	adenosine	that	binds	adenosine	receptor	2	(A2)	increases	
cyclic	 adenosine	monophosphate	 (cAMP)	with	 consequent	 immunosuppression	 due	 to	 the	
reduced	production	of	pro-inflammatory	cytokines	such	as	TNF-a	and	 IL-1b.	Moreover,	 the	
activation	of	A2	 receptors	 induces	 the	production	of	anti-inflammatory	 cytokines	 like	 IL-10	
(Johnston-Cox	 et	 al.	 2012).	 Although	MTX	 is	 the	most	 effective	 drug	 compared	with	 other	
DMARDs	and	bDMARDs,	 some	patients	do	not	 respond,	others	develop	 resistance	or	have	
important	side	effects	after	prolonged	use.	Most	severe	side	effects	associated	with	a	 long	
term	use	of	MTX	are:	hepatic	fibrosis,	pulmonary	fibrosis,	fatigue	and	renal	insufficiency	(Tian	
&	Cronstein	2007).		
1.4.3. Biological	DMARDs	
In	the	mid	1970’s	a	new	technology	allows	producing	monoclonal	antibodies	(Kohler	&	Milstein	
1975).	This	technological	progress	opens	the	road	to	a	new	treatment	opportunity	called	the	
antibody	 therapy.	 The	 potential	 of	 this	 treatment	 was	 immediately	 obvious,	 indeed	 new	
molecules	could	be	designed	and	produced	for	a	specific	 target	expressed	on	specific	cells,	
tissues	or	organs.	This	opportunity	allowed	to	increase	drug	specificity	decreasing	toxic	effects	
relative	to	traditional	chemical	compounds,	which	usually	act	with	unclear	mechanisms.	At	the	
moment,	 four	different	 targets	can	be	struck	with	bDMARDs	 for	RA	 treatment:	TNF-a,	 IL-6	
receptor,	CD20	and	CD80/CD86	(Smolen	et	al.	2016).	In	particular,	TNF-a	inhibitors	were	the	
first	biologicals	developed	to	treat	RA.	The	first	monoclonal	antibody	approved	blocking	TNF-
a	was	Infliximab	(Reviewed	in	Campbell	et	al.	2011),	a	chimeric	human-mouse	monoclonal	IgG.	
Whereas,	Adalimumab	was	the	first	full	human	IgG	approved	to	neutralize	TFN-a	(Rau	2002).	
Both	 became	 very	 popular	 because	 of	 the	 central	 role	 of	 TNF-a	 in	 the	 pathogenesis	 and	
progression	of	RA.	TNF-a	is	produced	mainly	by	T-cells	and	macrophages	infiltrated	into	the	
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synovial	membrane	and	its	inhibition	was	associated	to	a	decreased	level	of	pro-inflammatory	
cytokines	 such	 as	 IL-1,	 IL-6,	 IL-8	 and	 the	 growth	 factor	 GM-CSF	 (Butler	 et	 al.	 1995).	 The	
effectiveness	has	been	demonstrated	in	animal	models	of	RA	where	the	anti-TNF-a	treatment	
reduces	 paw	 swelling	 and	 histological	 severity	 (Williams	 et	 al.	 1992).	 These	 improvements	
where	 than	 confirmed	 in	 humans	 by	 several	 studies	 showing	 that	 anti-TNF-a	 inhibition	
prevents	 bone	 structural	 damage,	 improves	 physical	 function	 while	 slowing	 radiographic	
changes	in	joints	(Ma	&	Xu	2013)(Chen	et	al.	2006).	
1.4.4. Targeted	synthetic	DMARDs	
The	latest	drug	approved	to	treat	RA	is	Tofacitinib,	a	Janus	kinase	(JAK)	inhibitor.	Drugs	able	to	
target	one	specific	molecule,	 like	 JAK	 inhibitors,	are	 included	 in	a	new	class	of	drugs	called	
“targeted”	 synthetic	 DMARDs.	 It	 interferes	 with	 the	 JAK-STAT	 signaling	 pathway,	 which	 is	
activated	by	several	pro-inflammatory	cytokines	and	growth	factors	such	as	IL-6,	interferon-g	
and	GM-CSF.	Once	this	pathway	is	active,	it	promotes	the	expression	of	inflammatory	genes	
or	genes	 involved	 in	cell	survival	and	proliferation	(Ivashkiv	&	Hu	2003).	Over	a	period	of	2	
years,	Tofacitinib	was	superior	if	compared	with	Methotrexate,	both	as	monotherapy	(Lee	et	
al.	2014).		
1.4.5. Side	effects	of	RA	therapies	
As	previously	mentioned,	according	to	the	EULAR	recommendation	the	first	line	treatment	is	
based	on	DMARDs.	In	particular,	the	gold	standard	to	treat	RA	is	still	MTX	due	to	its	acceptable	
safety	profile,	low	cost	and	great	efficacy	to	prevent	cartilage	and	bone	destruction	(Shinde	et	
al.	2014).	Indeed,	biologicals	drugs	show	similar	improvement	than	MTX	(Favalli	et	al.	2012)	
but	are	associated	with	more	severe	side	effects.	Among	these,	rare	demyelinating	syndromes,	
lupus-like	 reactions,	 bacterial	 infections	 and	 the	 reactivation	 of	 tuberculosis	 (TB)	 are	
associated	with	the	inhibition	of	anti-TNF-a	(Botsios	2005);	common	but	tolerable	side	effects	
like	injection-site	reaction	and	infusion	are	also	related	to	the	TNF-a	blocking	(Scott	&	Kingsley	
2006).	 Safety	 concerns	were	 reported	about	 Tofacitinib	 treatment,	where	 respiratory	 tract	
infection,	 headache,	 and	 diarrhea	were	 the	most	 common	 side	 effects	 (Fleischmann	 et	 al.	
2012)(van	Vollenhoven	et	al.	2012).	Despite	MTX	 is	 still	 the	anchor	drug	 to	 treat	RA,	 some	
issues	are	reported	such	as	mouth	ulcers,	gastrointestinal	intolerance,	bone	marrow	and	liver	
toxicity.	Some	of	these	side	effects	could	be	overcome	with	folate	supplementation	(Whittle	
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&	Hughes	2004).	However,	one	third	of	the	patients	treated	with	MTX	had	to	discontinue	the	
treatment	after	2	years,	while	more	than	50%	discontinued	the	treatment	after	5	years	(Lee	et	
al.	2014).	Some	patients	discontinued	this	therapy	because	of	 inefficacy	while	other	due	to	
side	effects.	Pharmacogenetics’	studies	have	been	performed	in	order	to	find	genes	which	can	
help	to	predict	MTX	toxicity	but	inconsistent	data	have	been	produced	(Romao	et	al.	2014).		
1.5. Nanotechnology	and	Nanomedicine	
The	 term	nanotechnology	 is	defined	 in	 literature	with	different	shades	 to	explain	 its	broad	
meaning	and	the	wide	range	of	methods,	tools	and	possible	application.	For	the	purpose	of	
this	work	the	suitable	definition	 is	that	accepted	by	the	European	Medicines	Agency	(EMA)	
based	on	the	definitions	provided	by	the	UK	Royal	Society	and	Royal	Academy	of	Engineering	
report	 (Dowling	 et	 al.	 2004),	 the	 European	 Science	 Foundation	 foresight	 study	 on	
nanotechnology	(Moran	2005)	and	the	Vision	paper	and	Basis	for	strategic	research	agenda	
for	Nanomedicine	by	 the	European	Technology	Platform	on	Nanomedicine	 (Boisseau	et	 al.	
2005).	 Therefore,	 according	 to	 those	 documents,	 Nanotechnology	 is	 defined	 as	 “the	
production	and	application	of	structures,	devices	and	systems	by	controlling	the	shape	and	size	
of	materials	at	nanometre	scale.	The	nanometre	scale	ranges	from	the	atomic	level	at	around	
0.2	nm	 (2	Å)	up	 to	around	1000	nm”	while	Nanomedicine	 is	defined	as	 “the	application	of	
nanotechnology	in	view	of	making	a	medical	diagnosis	or	treating	or	preventing	diseases.	 It	
exploits	the	improved	and	often	novel	physical,	chemical	and	biological	properties	of	materials	
at	nanometre	scale”.	Despite	 the	 term	nanotechnology	became	popular	 in	1986,	 thanks	 to	
Professor	Kim	Erik	Drexler	who	used	it	in	the	title	of	his	book	“Engines	of	Creation:	The	Coming	
Era	of	Nanotechnology”	(Drexler	1986),	the	term	was	coined	by	Professor	Norio	Taniguchi	in	
1974	to	describe	the	precision	manufacture	of	materials	with	nanometre	tolerances	(Taniguchi	
&	Others	1974).	However,	it	is	important	to	mention	the	great	contribution	given	by	Richard	
Feynman	during	his	provocative	talk	under	the	title	“There’s	plenty	of	room	at	the	bottom”	to	
the	California	Institute	of	Technology.	He	foresees	the	potential	to	control	single	atoms	and	
molecules	 improving	 the	performance	of	 instruments	 such	as	 the	electron	microscopes.	 In	
conclusion,	he	foresees	“Nanotechnology”.	That	talk	 influenced	the	scientific	community	to	
challenge	 this	 research	 field	 and	 leading	 to	 the	 development	 of	 the	 scanning	 tunnelling	
microscope	 and	 the	 atomic	 force	 microscope	 (Toumey	 2009),	 breakthroughs	 which	 were	
predicted	 by	 Feynman’s	 talk	 years	 before.	 The	 potential	 offered	 by	 nanotechnology	 is	 still	
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underestimated,	 but	 the	 field	 of	 medicine	 is	 going	 to	 be	 revolutionised.	 Indeed,	 the	
opportunity	to	build	structures	in	the	same	scale	size	of	the	biomolecules	enhance	a	broad	set	
of	drugs	features.	
1.5.1. Nanocarriers	
The	 success	 of	 nanotechnology	 is	 due	 to	 the	 excellent	 and	unique	properties	 offered	 by	 a	
material	 in	 its	 nanometre	 scale.	 Nanomaterials	 find	 application	 in	 many	 different	 fields:	
electronics,	 green	 technology	 and	 alternative	 energy,	 coatings,	 industrial	 chemistry,	
nanorobotics,	cosmetics	and	biomedical.	For	examples,	silver	nanoparticles	are	widely	used	in	
disinfectants	 (Le	Ouay	&	 Stellacci	 2015)	while	 titanium	 dioxide	 and	 zinc	 oxide	 are	 used	 in	
sunscreen	and	cosmetics	(Smijs	&	Pavel	2011).	The	field	of	medicine	is	going	to	change	fast	
due	 to	 the	 influence	 of	 nanotechnology	 leading	 to	 the	 new	 field	 called	 nanomedicine.	 In	
particular,	nanoparticles	are	the	main	application	of	nanotechnology	in	the	medical	field	(Kim	
et	al.	2010).	The	success	of	nanoparticles	lies	in	the	advantages	offered	in	comparison	with	the	
free	 drugs.	 Indeed,	 drugs	 encapsulated	 in	 nanoparticles	 are	 protected	 from	 the	 biological	
environment,	 where	 enzymes	 could	 degrade	 rapidly	 drugs.	 Nanocarriers	 improve	 the	
concentration	of	the	drugs	into	the	selected	tissue	and	change	the	pharmacokinetics	of	a	drug.	
Moreover,	 nanocarriers	 increase	 the	 intracellular	 penetration	 allowing	 different	 entrance	
mechanisms,	different	from	those	used	by	the	free	drugs.	The	same	nanoparticles’	features	
are	now	exploited	to	improve	diagnosis,	increasing	the	contrast	and	the	sensitivity	of	currently	
used	diagnostic	probes	(Peer	et	al.	2007).	In	addition,	nanoparticles	allow	to	carry	at	the	same	
time	 diagnostic	 tracers	 and	 therapeutic	 compounds	 opening	 the	 way	 to	 the	 so	 called	
theranostics,	 or	 allow	 to	 deliver	 two	 drugs	 simultaneously,	 an	 option	 called	 combination	
therapy	 (Farokhzad	 &	 Langer	 2009).	 Several	 different	 kinds	 of	 nanocarriers	 have	 been	
produced,	 characterized	 and	 finally	 used	 for	 many	 different	 purposes:	 polymer-drug	
conjugates,	 lipid-based	 nanocarriers	 such	 as	 liposomes	 and	 micelles,	 carbon	 nanotubes,	
dendrimers,	 gold	 nanoparticles,	 nanoshells	 and	 polymeric	 nanoparticles	 (Figure	 5).	
Nanoparticles	can	be	divided	into	two	classes:	organic	and	inorganic	nanoparticles.	Inorganics	
nanoparticles	are	made	of	metal	atoms	(metallic),	non-metal	atoms	(organic)	or	a	mixture	of	
metal	and	non-metal	(semi-conducting).	Each	of	these	types	of	nanoparticles	shows	peculiar	
features	 and	 are	 used	 for	 different	 application.	Metallic	 nanoparticles	 usually	 find	medical	
application	 as	 diagnostic	 probes	 for	magnetic	 resonance	 imaging	 (MRI),	 positron	 emission	
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tomography	(PET),	X-ray	and	optical	imaging.	Organic	nanoparticles	can	be	made	of	different	
polymers	or	lipids	and	due	to	their	biodegradability	are	widely	used	for	drug	delivery	(Murthy	
2007).	
In	1995	the	first	formulation	of	liposomes	has	been	approved	by	Food	and	Drug	Administration	
(FDA)	under	the	trade	name	Doxil	(liposomes	loaded	with	doxorubicin)	for	the	treatment	of	
the	 Kaposi	 sarcoma.	 This	 formulation	 demonstrated	 an	 improved	 circulation	 half-life	 of	
doxorubicin	and	an	increased	accumulation	in	the	tumour	tissue	(Barenholz	2012)(Gabizon	et	
al.	 2003).	 To	 this	 day,	 11	 different	 formulations	 of	 liposomes	 have	 been	 approved	 for	 the	
treatment	of	different	diseases.	They	are	spherical	vesicles	essentially	made	of	phospholipids,	
which,	due	to	their	amphiphilic	nature,	are	able	to	self-assembly	in	aqueous	solution.	The	polar	
shell	 is	made	of	a	 lipid	bilayer,	which	 is	able	 to	hold	 lipophilic	molecules	between	 the	 two	
phospholipids	bilayer.	By	contrast,	the	aqueous	core	can	be	loaded	with	hydrophilic	molecules	
(Pattni	 et	 al.	 2015).	 The	 surface	 of	 these	 structures	 can	 be	 functionalized	 with	 different	
molecules	in	order	to	target	specific	kind	of	cells	or	tissues.	Despite	the	success	of	liposomes	
based	nanocarriers	as	drug	delivery	systems,	their	use	is	still	limited	by	some	technical	reasons.	
Indeed,	 liposomes	 are	 characterized	by	 low	 stability	 for	 long	 term	 storage	 and	 the	 limited	
amount	of	drug	that	can	be	loaded	(Sanna	et	al.	2014).	
Polymeric	micelles	are	self-assembled	core-shell	nanostructures	made	by	amphiphilic	block	
copolymers.	In	aqueous	solution,	the	hydrophobic	regions	of	the	block	copolymers	aggregate	
in	 order	 to	 reduce	 contact	 with	 water	 molecules	 producing	 core-shell	 vesicles.	 These	
structures	usually	found	application	in	the	delivery	of	hydrophobic	drugs	which	can	be	loaded	
into	the	core	of	these	structures	(Xu	et	al.	2013).	
Polymer	 drug	 conjugates	 were	 first	 described	 in	 1977	 when	 researchers	 reported	 no	
immunogenicity	of	bovine	serum	albumin	(BSA)	when	conjugated	to	polyethylene	glycol	(PEG)	
(Abuchowski	et	al.	1977).	 Indeed,	because	of	 its	 low	immunogenicity,	PEG	is	the	most	used	
polymer	 to	make	nanocarriers	 stealth	 to	 the	 immune	 system	 (Salmaso	&	Caliceti	 2013).	 In	
addition,	PEG	increases	the	solubility	of	the	attached	proteins	and	increases	proteins’	half-life	
in	the	bloodstream	because	of	their	higher	molecular	weight	(Pasut	&	Veronese	2012).	The	
prolonged	half-life	associate	to	the	use	of	PEG-conjugated	protein	was	demonstrated	with	a	
commercial	antibody	called	certolizumab	pegol,	a	Fab	fragment	(described	in	the	paragraph	
1.7.1)	able	to	block	TNF-a	and	conjugated	to	PEG	of	40kDa.	This	antibody,	now	used	to	treat	
RA,	shows	higher	 time	of	circulation	and	a	 lower	rate	of	kidney	elimination	 if	compared	 to	
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other	commercially	available	anti-TNF-a.	Moreover,	a	higher	tissue	penetration	was	reported	
for	PEG	conjugated	antibody	fragment.	In	fact,	PEG	increases	the	molecular	weight,	enhances	
the	retention	time	in	the	inflamed	tissue,	where	the	vessels	are	usually	characterized	by	their	
high	permeability	 (Palframan	et	 al.	 2009).	Another	 successful	polymer	used	as	a	 conjugate	
agent	is	hyaluronic	acid	(HA).	This	is	a	natural	polysaccharide	able	to	bind	its	receptor	CD44,	
which	has	been	found	to	be	overexpressed	in	inflamed	synovial	tissue.	For	this	reason,	HA	is	a	
molecule	suitable	 for	 target	drug	delivery	 in	 inflamed	 joints	of	RA	patients.	 Indeed,	HA	has	
been	used	in	conjugation	with	MTX	demonstrating	that	HA-MTX	is	able	to	reach	the	inflamed	
joint	in	a	higher	concentration	thus	showing	a	superior	therapeutic	efficacy	if	compared	with	
the	free	drug	(Shin	et	al.	2014).	Dendrimers	are	tree-like	branched	macromolecules	made	of	
natural	or	synthetic	elements.	They	have	a	central	inner	core	with	radially	attached	repeated	
units	 which	 possess	 several	 chemical	 functional	 groups	 nearby	 the	 surface	 (Pandita	 et	 al.	
2014).	Due	to	different	functional	end	groups,	they	are	multivalent	nanocarriers	able	to	carry	
several	kinds	of	molecules.	Dendrimers	have	been	used	to	treat	animal	model	of	rheumatoid	
arthritis	showing	great	ability	to	reduce	osteoclastogenesis	and	to	decrease	the	secretion	of	
pro-inflammatory	cytokines	(Bosch	2011).		
Carbon	 nanotubes	 are	 cylindrical	 nanostructure	 made	 of	 benzene	 rings.	 They	 can	 have	
different	 structures	 such	 as	 single-walled	 nanotubes	 (SWNTs)	 and	multi-walled	 nanotubes	
(MWNTs).	The	latter	is	made	of	multiple	rolled	layers	of	graphene	(Eatemadi	et	al.	2014).	These	
nanostructures	have	been	exploited	mainly	for	diagnostic	purpose.	Indeed,	 issues	regarding	
their	 toxicity	 are	 still	 under	 debate	 and	 limit	 their	 prolonged	 therapeutic	 use.	 Although,	
different	 approaches	 have	 been	 used	 to	 increase	 carbon	 nanotubes	 biocompatibility	 and	
biodegradability.	 To	 this	 aim,	 chemically	 functionalised	 carbon	 nanotubes	 show	 reduced	
toxicity	and	better	degradability	due	to	the	oxidative	enzymes	(Bianco	et	al.	2011).		
Polymeric	nanoparticles	(NPs)	represent	another	class	of	successful	nanocarriers,	which	has	
been	 used	 in	 medical	 application	 both	 for	 diagnostic	 and	 therapeutic	 purposes.	 They	 are	
composed	 of	 block	 copolymers	with	 different	 hydrophilicity,	 length	 and	molecular	weight,	
which	spontaneously	assembles	into	a	core-shell	structure	in	an	aqueous	environment.	High	
amounts	 of	 therapeutics	 can	 be	 loaded	 into	 the	 core	 of	 these	 structures	 and,	 due	 to	 the	
hydrophilic	 shell,	 encapsulated	 drugs	 are	 protected	 from	 the	 external	 environment	 (Hu	 &	
Zhang	2012).	 Initially,	polymeric	nanoparticles	were	mainly	produced	by	non-biodegradable	
polymers,	 such	 as	 polystyrene,	 polyacrylates,	 poly	 (methyl	 methacrylate)	 (PMMA)	 or	
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polymers	can	be	synthetic	such	as	poly	(e-caprolactone)(PCL),	poly	(lactide)(PLA),	poly	(lactide-
co-glycolide)	copolymers	(PLGA)	and	poly	(amino	acids)	or	can	be	natural	like	chitosan,	alginate	
and	 gelatine	 (Banik	 et	 al.	 2016).	 PLGA	 is	 one	 of	 the	 most	 used	 polymer	 due	 to	 its	
biodegradability.	It	is	hydrolysed	in	two	monomers,	one	of	lactic	acid	and	one	of	glycolic	acid	
which	 are	 both	 non-toxic	 molecules	 for	 the	 human	 body.	 In	 the	 same	 way	 PLA	 is	 a	
biocompatible	and	a	biodegradable	polymer	and	it	is	metabolized	in	monomeric	units	of	lactic	
acid,	which	is	a	natural	intermediate	of	anaerobic	respiration,	showing	very	poor	toxicity.	No	
toxicity	 was	 reported	 also	 for	 PCL	 which	 is	 degraded	 by	 hydrolysis	 of	 its	 ester	 linkages	
(Mahapatro	 &	 Singh	 2011)(Kumari	 et	 al.	 2010).	 PCL	 is	 characterized	 by	 very	 low	 in	 vivo	
degradation	time	and	high	drug	permeability	and	for	these	reasons	is	widely	used	for	tissue	
engineering	scaffolds	(Ulery	et	al.	2011).	PLGA,	PLA	and	PCL	were	approved	by	FDA	for	several	
applications	in	human	body.		
1.5.3. Properties	and	rational	design	of	nanoparticles	
In	 order	 to	 design	 successful	 nanocarriers	with	 a	 higher	 therapeutic	 efficacy	 or	 diagnostic	
sensitiveness	it	is	fundamental	to	rationally	design	nanocarriers	with	tissue	specificity	in	order	
to	avoid	unspecific	distribution	and	low	accumulation	of	the	molecules	in	the	target	cell/tissue.	
To	reach	this	aim,	a	rational	design	should	take	into	account	several	physicochemical	features	
of	the	polymers	and	the	final	structure.	Likewise,	the	design	should	consider	the	environment	
in	which	nanocarriers	will	be	injected	and	the	biological	barrier	to	cross	and	reach	the	final	
target	(Blanco	et	al.	2015).	The	route	of	administration	influences	the	biodistribution	and	the	
adsorption.	Indeed,	orally	administrated	nanoparticles	have	to	cross	the	gut	mucosa	to	reach	
the	 bloodstream.	 This	 route	 showed	 a	 slow	 rate	 of	 adsorption	 and	 only	 low	 amount	 of	
nanoparticles	reach	the	target	tissue.	By	contrast,	intravenously	administrated	nanoparticles	
showed	 100%	 of	 bioavailability	 and	 a	 fast	 biodistribution	 (Simon	 &	 Sabliov	 2014).	
Biodegradability	 and	 biocompatibility	 are	 indispensable	 traits	 to	 satisfy	 in	 order	 to	 design	
nanocarriers,	which	can	be	used	for	medical	purposes.	Indeed,	FDA	biodegradable	polymers	
are	usually	used	to	develop	new	nanotechnological	therapeutics	and	diagnostics.	Degradation	
time	of	biodegradable	polymers	depend	on	the	length	of	the	polymers	while	the	nanoparticles’	
shape	is	mainly	a	result	of	the	molecular	weight	and	the	polymer	concentration	as	well	as	the	
encapsulation	efficiency	(Danhier,	Ansorena,	et	al.	2012).	Size,	shape	and	features	of	the	shell	
surface,	such	as	the	charge,	define	their	biodistribution	and	stability	in	the	bloodstream.	Once	
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in	the	circulation,	nanoparticles	must	avoid	opsonisation	and	then	cross	the	blood	vessels	to	
arrive	 in	 the	 target	 tissue.	 The	 process	 of	 opsonisation	 includes	 the	 adsorption	 of	 plasma	
proteins,	 serum	 albumin,	 immunoglobulins	 and	 complement	 proteins	 on	 the	 surface	 of	
nanoparticles.	These	proteins	form	the	so	called	“protein	corona”,	which	is	responsible	of	a	
rapid	clearance,	hindrance	of	targeting	capacity,	and	induction	of	toxicity	(Nguyen	&	Lee	2017).	
Due	 to	 these	proteins	 adsorbed	on	 the	 surface,	 nanoparticles	 are	 often	 recognized	by	 the	
mononuclear	phagocyte	system	(MPS).	The	MPS	is	mainly	composed	by	macrophages	of	the	
spleen,	 lymph	nodes	and	liver,	which	contribute	to	the	phagocytosis	and	elimination	of	the	
nanoparticles	(Moghimi	&	Patel	1998).	The	formation	of	the	protein	corona	is	influenced	by	
different	 factors	 such	 as	 surface	 charge,	 hydrophobicity,	 nanoparticles	 size	 and	 functional	
groups	on	the	shell.	The	best	strategy	to	design	“stealth”	nanoparticles	is	to	cover	the	surface	
with	 non-immunogenic	 and	 hydrophilic	molecules	 able	 to	mask	 the	 hydrophobicity	 of	 the	
nanoparticles.	 The	 most	 widely	 used	 molecule	 is	 PEG,	 already	 used	 in	 conjugation	 with	
antibodies	to	increase	their	lifetime	(see	paragraph	1.5.1).	In	the	same	way,	when	PEG	is	used	
on	the	surface	of	nanoparticles,	it	increases	the	circulation	time	in	the	blood	(Hamilton	et	al.	
2002).	Moreover,	it	reduces	nanoparticles	aggregation	and	protein	corona	formation	(Fang	et	
al.	2009).	The	conformation,	 the	 length	and	the	density	of	PEG	are	features	that	affect	the	
circulation	 time	 of	 nanoparticles.	 In	 general,	 long	 chain	 of	 PEG	 (20-50	 kDa)	 are	 used	 in	
conjugation	with	small	protein	thus	preventing	renal	excretion,	while	short	PEG	chains	(3-10	
kDa)	are	usually	bound	on	 larger	nanoparticles	 (50-100nm)	because	an	 increased	diameter	
could	increase	the	interaction	with	the	MPS.	For	what	concerns	the	density,	it	is	known	that	
low	density	of	PEG	on	the	surface	of	nanoparticles	assumes	a	“mushroom”	conformation,	by	
contrast,	high	density	of	PEG	assumes	a	“brush”	conformation.	The	latter	increases	the	lifetime	
due	to	the	fact	that	high	density	of	PEG	masks	the	nanoparticles	from	the	MPS	(Jokerst	et	al.	
2011).	 Although,	 PEG	 is	 not	 the	 only	 stealth	material	 and	other	 hydrophilic	 polymers	with	
stealth	properties	can	be	used	such	as	polaxamer,	polyvinyl	alcohol,	poly(amino	acids)	and	
polysaccharides	(Huang	&	Guo	2011).	Advanced	strategies	to	produce	stealth	nanoparticles	
have	been	developed	using	cell	membranes	isolated	from	leukocytes	(Parodi	et	al.	2012)	or	
red	 blood	 cells	 (Hu	 et	 al.	 2011)	 showing	 an	 increased	 circulation	 time.	 Another	 important	
characteristic	 is	 the	 dimension	 of	 the	 nanoparticles.	 Indeed,	 nanoparticles,	 in	 order	 to	 be	
accumulated	 in	 the	 target	 tissue,	must	 cross	 the	 blood	 vessel	 wall.	 Usually	 healthy	 blood	
vessels	have	pore	size	about	5	nm.	Thus,	nanoparticles	with	a	diameter	less	than	5	nm	quickly	
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mechanism	 (Champion	&	Mitragotri	 2006).	 Another	 endocytic	 pathway	 able	 to	 internalize	
particles	with	a	big	diameter	is	called	macropinocytosis.	Through	this	pathway,	it	is	possible	to	
internalized	particles	with	a	diameter	between	0.5	and	10	µm.	Instead,	smaller	particles	with	
a	 diameter	 of	~120	 nm	 are	 internalized	 through	 the	 clathrin-mediated	 endocytosis	 (CME).	
Many	proteins	participate	in	the	formation	of	CME	vesicles,	in	particular	clathrin,	which	coats	
the	 vesicles	 inducing	 the	 curvature	 of	 the	 membrane.	 It	 has	 been	 proved	 that	 cationic	
nanoparticles	made	of	PLA-PEG	with	a	diameter	of	~100	nm	are	exclusively	 internalized	by	
CME	endocytosis	(Harush-Frenkel	et	al.	2007).	The	charge	effects	the	internalization,	indeed	
positively	charged	nanoparticles	are	attracted	by	negatively	charged	cell	surface	leading	to	an	
enhanced	 internalization	 via	 CME	 (Yameen	 et	 al.	 2014).	 Caveolae-mediated	 endocytosis	 is	
another	route	of	internalization	which	uses	a	specific	protein	(Caveolin)	to	form	the	vesicles	
with	a	flask-shaped	structure	of	60-80	nm	(Doherty	&	McMahon	2009).	This	is	the	preferential	
route	 used	 by	 viruses	 and	 other	 pathogens	 to	 enter	 into	 host	 cells	 because	 of	 bypass	 the	
lysosomes	(Carver	&	Schnitzer	2003).	For	the	same	reason,	this	pathway	should	be	convenient	
to	delivery	DNA	or	proteins.	Moreover,	 this	pathway	 received	great	attention	because	 it	 is	
involved	in	the	trans-endothelial	pathway	thus	could	be	exploited	to	design	particles	able	to	
deliver	 its	 content	across	 the	endothelial	 tissue	 (Oh	et	al.	 2007).	However,	 are	known	 two	
alternative	mechanisms	of	internalization,	which	do	not	require	the	presence	of	coat	proteins:	
clathrin	 and	 caveolin-independent	 endocytosis.	 Usually,	 vesicles	 of	 these	 pathways	 can	
internalize	particles	with	a	diameter	smaller	than	90	nm	(Yameen	et	al.	2014).		
Taking	into	account	all	these	knowledge,	it	is	reasonable	that	nanoparticles	with	a	diameter	
between	100	and	200	nm	should	be	the	best	choice	to	obtain	a	long-lasting	circulation.		
1.6. Passive	and	active	targeting	
The	process	by	which	the	nanoparticles	bind	their	target	tissue	can	be	passive	or	active.	The	
passive	targeting	does	not	require	a	specific	surface	functionalization	of	the	nanoparticles	and	
the	 movement	 and	 interaction	 are	 based	 only	 on	 the	 morphology	 and	 chemicophysical	
features.	 On	 the	 contrary,	 in	 the	 active	 targeting,	 particular	molecules	 conjugated	 on	 the	
nanoparticles’	surface	are	able	to	drive	them	into	a	specific	tissue.		
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1.6.1. Passive	targeting	
The	passive	targeting	coincides	with	the	Enhanced	Permeability	Retention	(EPR)	effect.	This	
effect	 was	 discovered	 in	 1986	 by	 Matsumura	 Y.	 &	 Maeda	 H,	 who	 described	 the	 higher	
accumulation	of	a	drug	polymer	conjugated,	 compared	 to	 the	 free	drug,	 into	 the	 tumor	of	
tumor	bearing	mice.	This	effect	 is	 the	 result	of	 the	pathophysiologic	 features	of	 the	 tumor	
hypervasculature	 coupled	 with	 poor	 lymphatic	 drainage	 (Figure	 7)	 (Matsumura	 &	 Maeda	
1986).	Indeed,	it	is	known	that	tumor	sites,	as	well	as	inflamed	tissue,	are	characterized	by	a	
prominent	neoangiogenetic	process	in	which	blood	vessel	showed	high	pressure	and	enhanced	
permeability	due	to	the	fact	that	fenestration	of	blood	vessel	in	this	pathological	tissues	can	
reach	 diameters	 of	 several	 µm	 (Hashizume	 et	 al.	 2000).	 In	 the	 inflamed	 tissue,	 several	
molecules	 such	 as	 histamine,	 bradykinin,	 leukotrienes,	 and	 serotonin	 contribute	 to	 the	
increased	permeability.	In	addition,	lack	of	tight	junction	between	endothelial	cells	and	lack	of	
functional	smooth	muscle	layer	around	the	blood	vessels	increase	the	process	of	extravasation	
(Nehoff	et	al.	2014).	Instead,	the	“retention”	is	the	result	of	the	lymphatic	vessels	impairment	
reported	 in	 tumor	 mass	 and	 in	 the	 hyperplastic	 synovial	 tissue	 of	 RA	 patients	 and	 other	
inflamed	tissue.	Indeed,	the	poor	drainage	of	the	lymphatic	vessels	has	been	demonstrated	in	
several	studies,	although	its	mechanism	is	not	yet	clear	(Bouta	et	al.	2015).	Since	healthy	tissue	
does	not	have	large	fenestration	in	the	blood	vessels	and	shows	regular	pressure	and	lymphatic	
vessels	functions,	nanocarriers	preferentially	reach	pathological	tissue	due	to	the	EPR	effect.	
This	mechanism	of	nanocarriers’	distribution	allows	 to	passively	delivery	drugs	with	higher	
concentration	 into	 the	affected	 tissue,	 increasing	 the	effectiveness	and	often	avoiding	 side	
effects	in	healthy	tissue	(Maeda	et	al.	2013).	It	is	known	that	small	particles	are	able	to	quickly	
reach	and	diffuse	in	the	target	tissue,	but	their	retention	would	be	low	and	clearance	would	
be	 fast.	 By	 contrast,	 particles	 with	 a	 bigger	 diameter	 reach	 their	 target	 slowly	 but	 their	
retention	and	clearance	would	be	enhanced.	Thus,	in	order	to	exploit	the	potential	of	the	EPR	
effect,	it	is	important	to	find	the	right	compromise	during	the	particles’	design	(Blanco	et	al.	
2015).		
1.6.2. Active	targeting	
Despite	advantages	of	the	passive	targeting,	some	limitations	are	known.	Indeed,	due	to	the	
variability	present	among	tumors	or	inflamed	tissues,	an	insufficient	amount	of	nanocarriers	
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such	 as	 peptides,	 vitamins	 and	 carbohydrates	 (Peer	 et	 al.	 2007).	 This	 approach	potentially	
increases	the	therapeutic	efficacy,	avoiding	off-target	side	effects.	Moreover,	a	reduction	in	
costs	of	disease	management	is	expected	because	the	doses	required	to	achieve	same	efficacy	
to	untargeted	drugs	might	be	lower	(Ferrari	et	al.	2015).		
1.7.1. Recombinant	antibodies	and	their	fragments	
The	antibodies	are	heterodimeric	proteins	composed	of	two	structural	elements	defined	as	
Heavy	(H)	and	Light	(L)	chains	because	of	their	aminoacidic	composition	and	molecular	weight.	
The	 heavy	 chain	 is	 made	 of	 440aa	 with	 a	 molecular	 weight	 of	 50kDa	 whereas	 the	 light	
counterpart	consists	of	220aa	with	a	molecular	weight	of	25kDa	(Wang	et	al.	2000).	Each	chain	
can	be	divided	into	two	basic	building	blocks:	the	variable	(V)	domain	(NH2-terminal),	able	to	
interact	with	the	antigen,	and	the	constant	(C)	domain	(COOH-terminal),	responsible	for	the	
effector	functions	such	as	the	macrophages	binding	or	the	complement	system	activation.	The	
heavy	chain	differs	from	the	light	chain	for	the	number	and	composition	of	these	functional	
domains:	the	light	chain	contains	one	constant	domain	(CL)	whereas	the	heavy	chain	could	be	
composed	by	either	three	or	four	constant	domains	(CH)	(Figure	8).	A	spacer	hinge	region	is	
located	 between	 CH1	 and	 CH2	 and	 confers	 particular	 flexibility	 to	 the	 final	 structure	
(Schroeder		Jr.	&	Cavacini	2010).	Depending	on	the	constant	composition,	the	human	heavy	
chains	could	be	classified	into	5	isotypes:	IgM,	IgG,	IgA,	IgD	and	IgE.	The	subclasses	IgM	and	IgE	
have	four	CH	in	contrast	to	the	others,	which	have	only	three	constant	domains	and	the	hinge	
region.	 In	 the	 variable	 domain	 three	 hypervariable	 loops	 are	 responsible	 for	 the	 antigen	
identification,	 called	 complementarity	 determining	 region	 (CDR)	 (Kim	 et	 al.	 2005).	 Three	
functional	 domains	 can	 be	 identified	 by	 papain	 digestion:	 two	 identical	 Fab,	 “fragment	
antigen-binding”,	which	consist	of	the	whole	L-chain	linked	with	the	VH	and	the	CH1	portion	
of	the	heavy	chain;	one	Fc,	“fragment	crystallisable”,	made	of	two	covalently	linked	CH2-CH3	
(or	CH2-CH3-CH4).	Instead,	the	immunoglobulin	can	be	cleaved	in	two	part	by	pepsin:	F(ab')2	
fragment	and	a	Fc	fragment.	The	Fab	can	be	separated	into	a	variable	fragment	(Fv),	made	of	
VH	and	VL	responsible	for	the	antigen	binding	and	another	fragment	composed	of	the	CL	and	
CH1.	Taking	advantage	of	this	functional	domains,	different	fragments	have	been	designed	and	
produced	by	recombinant	 technology.	 Indeed,	 fundamental	were	the	studies	conducted	by	
Kohler	and	Milstein	in	1975	(Kohler	&	Milstein	1975).	They	find	a	way	to	immortalize	B	cell	
precursors	 through	 the	 fusion	 with	 mouse	 myeloma	 cells	 to	 generate	 stable	 monoclonal	
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antibody	production.	Although	this	technique	provides	a	useful	method	for	the	production	of	
monoclonal	antibodies,	the	murine	origin	of	the	antibodies	causes	immunogenicity	in	humans	
(Schroff	 et	 al.	 1985)(LoBuglio	 et	 al.	 1989).	 However,	 improvement	 of	 molecular	 biology	
technique	 allows	 researchers	 to	 reduce	 the	 murine	 component	 in	 favor	 of	 the	 human	
component,	 generating	 different	 kinds	 of	 antibodies	 such	 as	 chimeric,	 humanized	 or	 fully	
human.	 Most	 successful	 engineered	 antibodies	 used	 are:	 the	 scFv	 (single	 chain	 fragment	
variable)	 or	 Fab.	 However,	 some	 issues	 are	 associated	 with	 the	 small	 molecular	 size:	 fast	
clearance,	poor	stability	and	monovalent	binding	to	the	antigen.	Although,	in	order	to	solve	
this	problem	two	different	engineered	antibodies	have	been	designed:	the	scFv-Fc	made	of	
the	scFv	fused	to	the	CH3-CH2	portion;	the	so	called	“minibody”	made	of	the	scFv	fused	to	the	
CH3.	These	formats	showed	an	improved	pharmacokinetics	with	a	prolonged	circulation	time,	
increased	tissue	penetration	and	enhanced	epitope	selectivity	(Olafsen	&	Wu	2010).	However,	
many	types	of	these	antibodies	have	been	used	as	therapeutic	agents	(immunotherapy)	or	as	
targeting	agents	for	nanocarriers.		
1.7.2. Peptides	
Although	the	antibodies	are	used	as	targeting	agents	able	to	delivery	nanocarriers	in	a	specific	
tissue,	 recently	 peptides	 have	 been	 used	with	 great	 success.	 Due	 to	 their	 small	 size,	 high	
stability,	low	immunogenicity	and	easy	production,	peptides	have	huge	potential	as	targeting	
agents	(Sanna	et	al.	2014)(Ferrari	et	al.	2015).	Peptides	containing	the	aminoacidic	sequence	
Arg-Gly-Asp	(RGD)	are	able	to	bind	integrins	avb3,	which	are	expressed	on	endothelial	cells	of	
the	 inflamed	 synovial	 tissue	 and	 tumours.	 Indeed,	 in	 a	 mice	 model	 of	 the	 syngeneic	
transplantable	liver	tumor	(TLT)	have	been	demonstrated	the	retarded	tumor	growth	and	a	
prolonged	survival	time	of	mice	treated	by	paclitaxel	(PTX)-loaded	RGD-nanoparticles	when	
compared	to	non-targeted	nanoparticles	(Danhier,	Pourcelle,	et	al.	2012).	In	the	same	way,	it	
has	been	proved	that	RGD-MTX-PLGA-Au	(gold)	nanoparticles	injected	in	a	model	of	collagen-
induced	arthritis	had	a	superior	therapeutic	efficacy,	compared	with	untargeted	nanoparticles,	
with	a	much	smaller	dosage	of	MTX	in	the	nanoparticles	(Lee	et	al.	2013).	
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The	use	of	immunotherapy	has	now	become	part	of	common	clinical	practice	for	the	treatment	
of	several	diseases.	Indeed,	immunotherapy	is	widely	used	to	treat	cancer	and	it	has	been	used	
to	 successful	 treat	 RA	 patients,	 improving	 their	 quality	 life.	 Although,	 their	 administration	
recognize	and	blocks	their	targets	systemically	enhancing	the	risk	of	developing	side	effects,	
such	as	bacterial	and	viral	infections.	Moreover,	high	costs	of	biological	drugs	are	holding	back	
their	widespread	usage.	For	these	reasons,	synthetic	DMARDs,	such	as	MTX,	are	still	the	anchor	
drugs	to	treat	RA.	Despite	the	improvements,	patients	are	treated	lifetime,	true	remission	is	
achieved	by	minority	and	most	of	them	have	to	face	relapses.		
In	this	scenario,	there	 is	the	need	to	develop	smart	drugs	with	tissue	specificity	able	to	act	
avoiding	systemic	complications,	increasing	the	effectiveness	and	reducing	doses	and	costs.		
Another	 important	aspect	 to	 improve	 is	 the	diagnosis	of	RA.	According	to	 the	classification	
criteria	for	rheumatoid	arthritis	2010	ACR/EULAR,	the	diagnosis	is	based	on	clinical	objective	
evaluations,	laboratory	tests	and	imaging	analysis.	Today,	radiography	is	the	mainstay	for	the	
diagnosis	and	follow-up	of	RA,	however,	radiations	limit	its	usage.	Moreover,	the	diagnosis	of	
the	disease	is	still	challenging	due	to	the	lack	of	tissue	specific	contrast	agents.		
For	 this	 reason,	 it	would	be	of	great	 interest	 to	develop	new	therapeutics	able	 to	 increase	
imaging	sensitivity	highlighting	synovial	inflammation,	cartilage	and	bone	erosions	maintaining	
low	toxicity	and	invasiveness,	possibly	developing	an	approach	that	allows	the	diagnosis	with	
biocompatible	 materials,	 suitable	 for	 different	 imaging	 techniques	 such	 as	 radiography,	
ultrasounds	and	magnetic	resonance	imaging.		
	
Nanotechnologies,	 particularly	 nanoparticles,	 have	 peculiar	 characteristics	 able	 to	 satisfy	
needs	 described	 above.	 In	 fact,	 nanoparticles	 can	 be	 functionalized	 with	 antibodies	 and	
peptides	that	specifically	target	tissues	or	cells,	allowing	the	delivery	of	a	considerable	amount	
of	their	payloads	(diagnostic	tracer	or	drugs).	This	strategy	should	increase	the	concentration	
of	 drugs	 or	 diagnostics	 into	 the	 desired	 tissue,	 allowing	 the	 reduction	 of	 the	 dose	 with	 a	
consequent	reduction	of	costs	and	side	effects.		
Our	group	in	2012	developed	an	anti-complement	C5	antibody	(ScFv-Fc)	able	to	specifically	
target	inflamed	synovial	tissues	due	to	the	synovial	homing	peptide	fused	with	the	Fc	portion	
of	 this	antibody	 (Macor	et	al.	2012).	This	 strategy	demonstrated	 that	 the	 targeted	peptide	
increases	 the	 accumulation	 of	 therapeutic	 or	 diagnostic	molecules	 onto	 the	microvascular	
endothelial	tissue	of	the	inflamed	RA	tissue.		
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As	 a	matter	 of	 fact,	 neoangiogenesis	 is	 a	 key	 process	 in	 the	 development	 of	 RA	with	 the	
involvement	of	adhesion	molecules,	cytokines	and	chemokines,	regulating	the	inflammatory	
process	 and	 in	 particular	 allowing	 inflammatory	 cells	 infiltration	 in	 the	 synovial	
microenvironment.	
	
The	aim	of	this	work	is	to	design,	produce	and	characterize	a	diagnostic	or	drug	delivery	system	
specific	for	the	inflamed	synovial	tissue	combining	a	targeting	strategy	based	on	the	synovial	
peptide	already	used	by	us	with	the	potential	features	of	the	biodegradable	nanoparticles.	In	
particular,	the	synovial	peptide,	specific	for	the	inflamed	synovia,	has	been	conjugated	on	the	
surface	of	biodegradable	polymeric	nanoparticles,	which	in	turn	can	be	loaded	with	drugs	(in	
this	case	MTX)	or	conjugated	with	diagnostic	tracers	(Cy5.5,	a	near	infrared	dye).	This	plan	aims	
to	 demonstrate	 in	 vivo,	 using	 animal	 models	 of	 rheumatoid	 arthritis,	 that	 targeted	
nanoparticles	(tBNPs),	compared	to	untargeted	nanoparticles	(BNPs),	are	able	to	specifically	
target	the	inflamed	synovial	tissues.		
Labelled	 tBNPs	 will	 have	 the	 possibility	 to	 concentrate	 into	 inflamed	 synovial	
microenvironment	providing	information	about	the	stage	of	the	pathology.	
The	local	drug	delivery	through	tBNPs-MTX	should	provide	greater	therapeutic	efficacy	than	
free	MTX,	using	lower	doses	of	MTX	encapsulated	in	tBNPs;	this	will	retain	its	effectiveness	
reducing	side	effects.	
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3.1. Production	of	the	targeting	molecule	
The	sequence	of	the	synovial	peptide,	which	is	a	peptide	of	9	aminoacids	(CKSTHDRLC),	used	
to	drive	nanoparticles	into	the	inflamed	synovial	tissue,	has	been	previously	cloned	in	fusion	
with	a	ScFv-Fc	in	order	to	generate	the	targeting	molecule	(Macor	et	al.	2012).		
The	monoclonal	cell	line	transfected	with	the	vector	pcDNA3.1/Hygro+	coding	for	the	targeting	
molecule	 (ScFv-Fc-synovial	 peptide)	 has	 been	 cultured	 in	 the	 CELLineTM	 Device	 (BD	
Biosciences).	This	device	is	a	small	bioreactor,	which	allows	reaching	a	high	amount	of	proteins	
compared	with	traditional	culture	flasks.	First,	the	cells	have	been	expanded	in	a	T75	tissue	
culture	flask	in	ProCHO5	(Lonza),	penicillin	10U/mL	(Sigma),	streptomycin	1μg/mL	(Sigma),	L-
glutamine	2mM	(Sigma),	FBS	10%	(fetal	bovine	serum)	and	Hygromycin	B	200μg/mL	(Sigma).	
Once	the	confluence	has	been	reached,	the	cells	have	been	detached	by	Trypsin	0.25mM-EDTA	
(Ethylene	diamine	 tetra	acetic	acid)	 (Sigma)	and	 resuspended	with	15mL	ProCHO5	 (Lonza),	
penicillin	10U/mL	(Sigma),	streptomycin	1μg/mL	(Sigma),	L-glutamine	2mM	(Sigma),	FBS	10%	
(fetal	 bovine	 serum),	 Hygromycin	 B	 200μg/mL	 (Sigma)	 to	 a	 final	 concentration	 of	 1x106	
cells/mL.	Thus,	cells	have	been	added	 to	 the	cultivation	chamber	while	300mL	of	ProCHO5	
(Lonza)	have	been	added	to	the	nutrient	supply	chamber.	The	cells	have	been	cultivated	at	
37°C	with	5%	of	CO2.	Twice	a	week	the	supernatant	containing	the	targeting	molecule	has	been	
collected	 from	 the	 cultivation	 chamber	and	 replaced	with	15x106	 fresh	 cells.	 The	 collected	
supernatant	has	been	centrifuged	at	1500	g	for	20	minutes	to	remove	debrides	and	cells.		
3.2. Purification	of	the	targeting	molecule	
The	targeting	molecule	has	been	purified	by	affinity	chromatography	using	the	HiTrap	rProtein	
A	FF	1	mL	 (Amersham	Biosciences).	 The	column	has	been	equilibrated	with	20mM	sodium	
phosphate	buffer	pH	7	(equilibrating	buffer)	and	the	supernatant	passed	through	the	column	
with	a	flow	of	1mL/minute	with	the	help	of	a	peristaltic	pump.	Afterwards,	the	column	has	
been	washed	with	 the	 same	equilibrating	 buffer	 and	 finally,	 the	 target	molecule	 has	 been	
eluted	using	0.1	M	sodium	citrate	buffer	pH	3.0	(elution	buffer).	Fractions	of	1.5mL	have	been	
collected	 and	 quickly	 equilibrated	with	 300μL	 1	M	 Tris-HCl	 pH	 9.0	 (neutralizing	 buffer)	 to	
restore	 the	 pH	 to	 a	 physiological	 value.	 Finally,	 these	 fractions	 containing	 the	 purified	
antibodies	have	been	dialyzed	with	DPBS	O/N	at	4°	quantified	by	absorbance	assay	at	A280nm	
using	a	spectrophotometer	(Eppendorf	BioPhotometer	Plus).	
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3.3. SDS	page	and	Western	blot	of	the	target	molecule	
Fractions	containing	the	purified	targeting	molecules	have	been	subjected	to	an	SDS	page.	The	
gels	 were	 characterized	 by	 stacking	 4%	 and	 resolving	 10%	 acrylamide	 concentration.	 In	
particular,	the	stacking	was	made	with	Acrylamide/Bis-acrylamide	30%	solution	(Sigma),	Tris-
HCl	 130mM	 pH	 6.8,	 SDS	 0,1%,	 Ammonium	 persulfate	 0,1%	 and	 TEMED	
(N,N,N’,N’tetrametiletilendiamina)	 0,01%	 (Sigma).	 The	 resolving	 was	 made	 with	
Acrylamide/Bis-acrylamide	30%	solution	(Acrylamide	29.2g/	Bis-acrylamide	0.8g	in	100mL	of	
H2O)	(Sigma),	Tris-HCl	400mM	pH	8.8,	SDS	0,1%,	Ammonium	persulfate	(APS)	0,1%,	TEMED	
0,01%	(Sigma).	The	gels	have	been	prepared	by	Mini-PROTEAN,	Tetra	Vertical	Electrophoresis	
Cell,	Biorad	with	a	thickness	of	0.75mm.	For	reduced	conditions,	samples	have	been	diluted	in	
sample	buffer	(Tris-HCl	61.5mM	pH	6.8,	SDS	2.5%,	Glycerol	10%,	bromophenol	blue	0,0025%,	
β-mercaptoethanol)	and	then	boiled	for	5’.	The	run	has	been	performed	in	running	buffer	(Tris-
HCl	50mM,	Glycine	384mM,	SDS	0,1%)	at	15mA	until	proteins	reached	the	running	gel,	then	
the	 current	 has	 been	 increased	 to	 20mA.	 Proteins	 separated	 by	 SDS	 page	 have	 been	
transferred	to	nitrocellulose	membrane	(GE	Healthcare,	Amersham	UK)	by	Western	blot	using	
a	Mini	Trans-Blot®	Module,	Bio-rad.	The	transfer	has	been	performed	at	3.5mA	cm2	for	45’	in	
transfer	 buffer	 (Tris-HCl	 25mM,	 Glycine	 192mM,	Methanol	 20%,	 pH	 8.3).	 Afterwards,	 the	
membrane	has	been	blocked	with	2%	of	skim	milk	(S.M.)	in	PBS	at	4°C	overnight.	Then,	the	
membrane	has	been	washed	three	times	with	wash	buffer	(0,1%	of	Tween	20	(Polyoxyethylene	
Sorbitan	monolaurate)(Sigma)	 in	PBS)	and	incubated	1h	RT	(room	temperature)	in	agitation	
with	the	primary	antibody	mouse	anti-SV5-biotinylated	(homemade	produced)	diluted	1:2000	
in	the	diluent	buffer	(0,1%	S.M.	and	0,05%	Tween	20	in	PBS).	Then	the	membrane	has	been	
washed	 three	 times	with	wash	 buffer	 and	 incubated	 30’	 RT	 in	 agitation	with	 Streptavidin-
alkaline	phosphatase	(Sigma)	diluted	1:2000	in	diluent	buffer.	Finally,	the	membrane	has	been	
washed	 three	 times	 and	 developed	 with	 0,3	 mg/ml	 of	 BCIP	 (5-Bromo-4-Chloro-3-Indolyl-
phosphate,	 Sigma)	 and	 0,6mg/ml	 of	 NBT	 (Nitro	 Blue	 Tetrazolium,	 Sigma)	 in	 alkaline	
phosphatase	buffer	(Tris-HCl	100mM,	NaCl	0,1M,	MgCl2	5mM,	pH	9.6).		
3.4. Nanoparticles	production	
In	 collaboration	 with	 Prof.	 Luis	 Nunez	 founder	 of	 BioTarget,	 company	 based	 in	 Chicago,	
nanoparticles	have	been	produced	under	 class	 100	 clean	 room	condition	using	 a	patented	
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technology	and	methodology	described	in	the	patent	number	US20080187487	A1.	Polymers	
used	 are:	 COOH-poly(ethylene	 glycol)-b-polylactide	 (PEG-b-PLA)	 and	 Poly(caprolactone)-
COOH	(PCL).	Methotrexate	has	been	purchased	from	TEVA.	The	targeting	molecule,	provided	
by	us,	have	been	conjugated	on	the	surface	of	the	nanoparticles	exploiting	its	primary	amines,	
which	can	react	with	polymers	functionalized	with	NHS	groups.	Nanoparticles	produced	have	
been	resuspended	in	PBS	pH	7.4	with	10%	of	bovine	serum	albumin	(BSA).		
3.5. Characterization	of	nanoparticles	by	DLS,	Nanoparticles	tracking,	
TEM	and	STEM.	
Nanoparticles	 produced	 have	 been	 characterized	 by	 Dynamic	 light	 scattering	 (DLS).	 The	
hydrodynamic	diameter	distribution	has	been	measured	using	a	Malvern	Nano	ZS	instrument	
(Malvern	Instruments,	Ltd,	Malvern,	UK).	Then,	nanoparticles	diluted	1:100	in	ultrapure	H2O	
have	 been	 analyzed	 by	 Malvern	 NanoSight	 LM10.	 Through	 this	 technique	 diameter	 and	
number	of	nanoparticles	have	been	determined.	For	transmission	electron	microscopy	(TEM)	
analysis,	 nanoparticles	 have	 been	 diluted	 1:50	 in	 ultrapure	 H2O	 and	 then	 a	 drop	 of	
nanoparticles’	solution	have	been	deposited	on	a	carbon	foil	supported	on	copper	microgrids.	
Images	have	been	acquired	by	Philips	CM100	TE	microscope	(Philips	Research,	Eindhoven,	The	
Netherlands)	 operating	 at	 80kV.	 For	 scanning	 transmission	 electron	 microscopy	 (STEM)	
analysis,	nanoparticles	have	been	diluted	1:50	in	ultrapure	H2O	and	images	acquired	with	a	
GAIA	3	Tescan	microscopy	(Tescan,	Czech	Republic)	with	a	STEM	detector	operating	at	30kV.		
3.6. MTT	viability	assay	
In	order	to	test	the	ability	of	BNPs-MTX	to	affect	endothelial	cells	and	to	demonstrate	that	
empty	BNPs	do	not	show	toxic	effects,	5x103	EA.hy926	cells	have	been	seeded	in	wells	of	a	96	
well	cell	culture	plate	(Sarstedt).	Cells	have	been	cultured	at	37°C	with	5%	of	CO2	in	Dulbecco's	
Modified	 Eagle's	 Medium	 (DMEM)	 supplemented	 with	 penicillin	 10U/mL	 (Sigma),	
streptomycin	1μg/mL	(Sigma),	L-glutamine	2mM	(Sigma)	and	FBS	10%.	After	cells	adhered	to	
the	wells,	 different	 amounts	 of	 nanoparticles	 have	 been	 incubated	 for	 48h.	 Then,	 20µL	 of	
[5mg/mL]	 MTT	 formazan	 (1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan)	 have	 been	
added	to	each	well	for	4h.	Afterwards,	the	plate	has	been	centrifuged	at	2250	g	in	order	to	
precipitate	all	the	formazan	crystals	and	the	supernatant	have	been	discarded.	Finally,	each	
well	has	been	resuspended	with	200µL	of	dimethyl	sulfoxide	(DMSO)	and	the	absorbance	have	
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been	measured	at	570nm	by	Infinite	M200	Pro	plate	reader	(Tecan).	The	%	of	viable	cells	have	
been	calculated	using	not	treated	cells	as	the	reference	of	100%	viable.	
3.7. Release	of	MTX	from	nanoparticles	
The	release	of	MTX	from	nanoparticles	has	been	quantified	by	dialysis.	 In	particular,	200µL	
[2mg/mL]	 of	 nanoparticles	 have	 been	 placed	 in	 a	 dialysis	 device	 for	 small	 volumes	with	 a	
dialysis	 membrane	 characterized	 by	 a	 molecular	 weight	 cut-off	 (MWCO)	 of	 3,5	 kDa	 and	
immersed	in	10mL	of	PBS	pH	7.4	at	37°C	in	slight	agitation	for	24h.	During	the	first	hour,	200µL	
of	PBS	of	the	dialysis	has	been	collected	every	15’,	while	in	the	second	hour	only	two	samples	
have	been	collected	(every	30’).	Then,	only	one	sample	has	been	collected	at	3,	4	and	5h.	The	
last	samples	have	been	collected	at	24h.	As	a	control,	the	same	procedure	has	been	used	to	
quantify	 the	 dialysis	 release	 of	 200µL	 of	 non-encapsulated	MTX	 [2mg/mL].	 150µL	 of	 each	
sample	collected	has	been	placed	 in	a	96	well	plate	 (Corning	96	well	 flat	 clear	polystyrene	
plate)	and	quantified	by	spectrophotometric	 readings	at	310nm	by	 Infinite	M200	Pro	plate	
reader	(Tecan).	The	optical	density	of	150µL	of	MTX	[2mg/mL]	diluted	in	10mL	of	PBS	have	
been	used	as	the	reference	of	100%	of	MTX	released.	The	amount	of	released	MTX	have	been	
calculated	as	follow:	(OD	samples	x	100)/	OD	100%	MTX	in	solution.	
3.8. Labelling	of	the	targeted	molecule	and	nanoparticles	
The	targeting	molecule	and	the	nanoparticles	have	been	labelled	with	fluorescent	probes	in	
order	 to	 be	 detectable	 with	 several	 techniques.	 In	 particular,	 Fluorescein	 Isothiocyanate	
Isomer	 I	 (FITC)	 (Sigma)	have	been	used	 for	 green	 fluorescence	at	 488nm,	while	 FluoroLink	
Cy5.5	Monofunctional	Dye	(GE	Healthcare)	have	been	used	for	near-infrared	fluorescence	at	
695nm.	For	FITC	labeling,	1mg	of	nanoparticles	have	been	centrifuged	at	5900g	for	1’30”	and	
resuspended	in	500µL	of	sodium	carbonate	buffer	pH	9.3	(repeat	this	step	three	times).	Then,	
50µL	of	FITC	[1mg/mL]	in	DMSO	has	been	added	drop	by	drop	in	slight	agitation	and	finally	
placed	 in	 a	 rotating	 mixer	 overnight	 (O/N)	 at	 4°C.	 Afterwards,	 add	 NH4Cl	 to	 a	 final	
concentration	of	50mM	and	incubate	2h	at	4°C.	Finally,	nanoparticles	have	been	centrifuged	
at	5900g	for	1’30”	and	resuspended	in	500µL	of	PBS	(repeat	this	step	three	times).	The	same	
procedure	has	been	used	to	label	1mg	of	targeting	molecule	by	replacing	the	centrifugation	
step	with	 a	 dialysis	 performed	O/N	 at	 4°C	 using	 dialysis	 tubes	with	 a	MWCO	 of	 12.4	 kDa	
(Spectra/Por).	 Instead,	 for	 the	Cy5.5	 labeling	a	commercial	 kit	has	been	used	 to	 label	both	
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nanoparticles	and	 the	 targeted	molecule.	First,	 1mg	of	nanoparticles	or	 targeting	molecule	
have	 been	 resuspended	 in	 1mL	 of	 sodium	 carbonate	 buffer	 pH	 9.3,	 respectively	 by	
centrifugation	 and	 by	 dialysis	 as	 described	 for	 FITC	 labeling.	 Then,	 the	 solutions	 with	
nanoparticles	 or	 the	 targeting	 molecule	 have	 been	 incubated	 into	 the	 commercial	 vials	
containing	the	powder	of	Cy5.5	for	30’	RT.	To	eliminate	the	excess	of	dye,	nanoparticles	have	
been	centrifuged	at	5900g	for	1’30”	and	resuspended	in	PBS	pH	7.4	(repeat	this	step	three	
times),	while	the	targeting	molecule	has	been	dialyzed	using	dialysis	tubes	with	a	MWCO	of	
12.4	 kDa.	 The	 amount	 of	 Cy5.5	 associated	 with	 the	 nanoparticles	 or	 with	 the	 targeting	
molecule	has	been	quantified	by	spectrophotometric	methods.	A	molar	extinction	coefficient	
of	250,000	M-1cm-1	at	678nm	has	been	used	for	Cy5.5,	while	a	molar	extinction	coefficient	of	
68,000	M-1cm-1	at	494nm	has	been	used	for	FITC.		
3.9. Staining	of	tissue	sections	
3.9.1. Preparation	of	paraffin	embedded	sections	of	human	synovial	
tissues	
Paraffin	 embedded	 synovial	 tissues,	 obtained	 from	 patients	 with	 RA,	 have	 been	 kindly	
provided	by	Prof.	Jessica	Bertrand.	First,	sections	of	7µm	thick	have	been	cut	by	microtome	
hyrax	m55	(Carl	Zeiss),	dried	for	2h	at	RT	and	baked	at	55°C	for	2h.	Slices	have	been	de-waxed	
by	immersion	in	Xylene	twice	for	5’	followed	by	one	wash	in	100%	Ethanol	(2’),	one	in	96%	
Ethanol	 (2’),	 one	 in	 80%	 Ethanol	 (2’)and	 one	 in	 70%	 Ethanol	 (2’).	 Then,	 slides	 have	 been	
rehydrated	 in	distilled	H2O	for	2’	and	then	soaked	 in	TBS	 for	2’.	Antigen	retrieval	has	been	
performed	enzymatically	with	a	 solution	of	0.05%	Trypsin,	0.5%	CaCl2	 in	distilled	H2O.	Few	
drops	of	this	solution	have	been	placed	on	the	slices	and	incubated	at	37°C	for	20’.	Afterward,	
slices	have	been	washed	with	distilled	H2O	and	blocked	for	30’	at	RT	in	a	humid	chamber	with	
blocking	buffer	(2%	serum	of	the	animal	in	which	has	been	developed	the	secondary	antibody	
in	PBS)	in	order	to	prevent	unspecific	antibody	binding.	The	excess	of	blocking	buffer	has	been	
removed	 and	 the	 primary	 antibody	 (concentration	 depends	 on	 the	 primary	 antibody,	 see	
below)	has	been	incubated	at	4°C	O/N	in	the	diluent	buffer	(0,2%	BSA	and	0,05%	Tween20	in	
PBS).	Then,	one	wash	of	5’with	gentle	rocking	has	been	performed	in	PBS	and	two	washes	of	
5’	have	been	done	with	1	‰	of	Triton	x100	in	PBS.	A	secondary	antibody	conjugated	with	a	
fluorescent	 probe	 and	 diluted	 (concentration	 depend	 on	 the	 secondary	 antibody)	 in	 the	
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diluent	buffer	has	been	incubated		at	RT	for	1h.	Three	washes	have	been	performed	as	before	
and	nuclei	have	been	stained	with	DAPI	diluted	in	PBS	1:1000	incubated	for	5’	at	RT.	Finally,	
usual	washes	have	been	done	and	slices	have	been	mounted	with	Mowiol	anti-fade	medium	
(Polysciences,	 Inc.).	 Sometimes,	 a	 secondary	 antibody	 conjugated	 to	 streptavidin	 has	 been	
used,	in	this	case,	an	additional	step	of	washes	and	incubation	with	biotin	conjugated	probe	
was	required.		
Staining	with	ScFv-Fc-synovial	peptide	(target	molecule)	
This	molecule	has	been	used	with	a	final	concentration	of	10µg/mL	and	incubated	at	4°C	O/N.	
Co-staining	have	been	performed	with	 the	 target	molecule	 already	 conjugated	 to	Cy5.5	or	
FITC.	 Otherwise,	 in	 order	 to	 detect	 the	 target	 molecule,	 a	 mouse	 anti-SV5	 (homemade	
antibody	used	1:200	in	the	diluent	buffer)	able	to	bind	the	tag	sequence	SV5	present	into	the	
target	molecule	have	been	used.	Finally,	a	goat	anti-mouse	Alexa	Fluor	488	(Thermo	Fisher)	or	
a	goat	anti-mouse	Alexa	Fluor	594	(Thermo	Fisher)	have	been	used	1:200	in	diluent	solution.		
Staining	of	vWF.		
A	rabbit	anti-vWF	(Dako)	has	been	used	1:400	in	the	diluent	buffer,	in	turn,	recognized	with	
goat	anti-rabbit-Cy3	(Jackson)	1:200	in	diluent	buffer.	
Staining	of	CD34+.		
A	rabbit	anti-CD34	(Bioss)	has	been	used	1:200	in	the	diluent	buffer,	in	turn,	detected	with	a	
goat	anti-rabbit-Cy3	(Jackson)	1:200	in	the	diluent	buffer	
Staining	of	nuclei	
Nuclei	have	been	stained	with	DAPI	(4',6-diamidin-2-phenylindole)	(Sigma)	diluted	1:1000	in	
PBS.	
3.9.2. Preparation	of	frozen	sections	of	AIA	and	CIA	
Tissues	collected	from	rats	and	mice	have	been	included	in	a	biocompatible	gelatinous	matrix	
with	polyvinyl	alcohol	10%	and	polyethylene	glycol	4%	(Tissue	Tek	OCT)	and	finally	frozen	at	-
80°C.	 Sections	 of	 7	µm	 thick	 have	 been	 cut	 by	 cryostat	 Leica	 CM	3050	 S	 equipped	with	 a	
microtome	at	-22°C.	Sections	are	dried	O/N	at	RT	and	then	stored	at	-20°C.	
3.9.3. Staining	of	frozen	sections	with	antibodies	
Sections	stored	at	-20°C	have	been	thawed	for	5	minutes	at	RT	and	fixed	with	cold	Acetone	
(Carlo	Erba)	for	15’	at	4°C.	Then,	sections	have	been	rehydrated	with	0.9%	NaCl.	Samples	have	
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been	blocked	with	blocking	buffer	(2%	of	serum	of	the	animal	in	which	has	been	developed	
the	secondary	antibody	in	PBS)	for	30’	RT	in	a	humid	chamber.	Sections	have	been	incubated	
with	 the	 primary	 antibody	 (concentrations	 depend	 on	 the	 antibody,	 see	 below)	 diluted	 in	
diluent	(0,2%	BSA	and	0,05%	Tween20	in	PBS)	at	4°C	O/N	and	then	one	wash	of	5’with	gentle	
rocking	has	been	performed	in	PBS	and	two	washes	of	5’	have	been	done	with	1	‰	of	Triton	
x100	in	PBS.	Afterwards,	the	secondary	antibody	(concentrations	depend	on	the	antibody,	see	
below)	diluted	in	diluent	has	been	incubated	for	1h	RT	and	then	washed	as	before.	Nuclei	have	
been	stained	with	DAPI	diluted	in	PBS	1:1000	incubated	for	5’	at	RT.	After	usual	washes,	slices	
have	 been	 mounted	 with	 Mowiol	 anti-fade	 medium.	 Sometimes,	 a	 secondary	 antibody	
conjugated	 to	 streptavidin	 has	 been	 used,	 in	 this	 case,	 an	 additional	 step	 of	 washes	 and	
incubation	with	biotin	conjugated	probes	was	required.	
Staining	with	ScFv-Fc-synovial	peptide	(target	molecule)	
This	molecule	has	been	used	with	a	final	concentration	of	10µg/mL	and	incubated	at	4°C	O/N.	
Co-staining	have	been	performed	with	the	targeting	molecule	already	conjugated	to	Cy5.5	or	
FITC.	 Otherwise,	 in	 order	 to	 detect	 the	 targeting	molecule,	 a	mouse	 anti-SV5	 (homemade	
antibody	used	1:200	in	the	diluent	buffer)	able	to	bind	the	tag	sequence	SV5	present	into	the	
targeting	molecule	have	been	used.	Finally,	a	goat	anti-mouse	Alexa	Fluor	488	(Thermo	Fisher)	
or	a	goat	anti-mouse	Alexa	Fluor	594	 (Thermo	Fisher)	have	been	used	1:200	 in	 the	diluent	
buffer.		
Staining	of	vWF.		
A	rabbit	anti-vWF	(Dako)	has	been	used	1:400	in	the	diluent	buffer,	in	turn	recognized	with	
goat	anti-rabbit-Cy3	(Jackson)	1:200	in	the	diluent	buffer.	
Staining	of	C3	
A	goat	anti-C3	(Cappel)	has	been	used	1:50	in	the	diluent	buffer,	in	turn	recognized	with	rabbit	
anti-goat-TRITC	(Sigma)	1:100	in	the	diluent	buffer.		
Staining	of	nuclei	
Nuclei	have	been	stained	with	DAPI	(4',6-diamidin-2-phenylindole)	(Sigma)	diluted	1:1000	in	
PBS.	
3.9.4. Staining	of	frozen	sections	with	nanoparticles	
In	order	to	study	the	binding	of	BNPs	and	tBNPs	on	the	synovial	tissue	of	rats,	sections	stored	
at	 -20°C	have	been	thawed	for	5	minutes	at	RT	and	fixed	with	4%	paraformaldehyde	(PFA)	
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(Sigma)	 for	 15’	 RT.	 Then,	 sections	have	been	 rehydrated	with	0.9%	NaCl	 and	blocked	with	
universal	blocking	buffer	(2%	of	BSA,	0,25%	of	casein	and	0,10%	of	gelatin	in	PBS)	for	30’	at	RT	
in	a	humid	chamber.	Afterwards,	10µg	of	BNPs-FITC	and	tBNPs-FITC	have	been	incubated	1h	
at	37°C.		Finally,	three	washes	have	been	performed	to	remove	unspecific	bound	nanoparticles	
and	slices	have	been	mounted	with	Mowiol	anti-fade	medium.	
3.9.5. Staining	of	viable	EA.hy926	cells	with	nanoparticles	
EA.hy	926	endothelial	cells	have	been	used	to	test	the	binding	of	tBNPs	to	endothelial	cells.	In	
particular,	3x104	cells	have	been	cultured	 in	each	well	of	an	X-well	Tissue	Culture	Chamber	
(Sarstedt)	for	high-resolution	microscopy.	Cells	have	been	cultured	at	37°C	with	5%	of	CO2	in	
DMEM	 supplemented	 with	 penicillin	 10U/mL	 (Sigma),	 streptomycin	 1μg/mL	 (Sigma),	 L-
glutamine	2mM	(Sigma)	and	FBS	10%.	20x107	BNPs-Cy5.5	and	tBNPs,	normalized	after	Cy5.5	
labeling	for	their	number	of	nanoparticles	by	NanoTrack	analysis,	have	been	incubated	for	1h	
at	37°C.	Afterwards,	three	washes	have	been	performed	with	PBS	and	then	cells	have	been	
fixed	15’	with	4%	PFA.	Other	three	washes	have	been	performed	to	remove	excess	of	PFA	and	
finally	 nuclei	 have	 been	 stained	 with	 DAPI	 (4',6-diamidin-2-phenylindole)	 (Sigma)	 diluted	
1:1000	in	PBS.	Two	more	washes	have	been	done	and	then	glass	microscope	slides	have	been	
detached	from	the	chamber	vessel	in	order	to	mount	the	slides	with	Mowiol	anti-fade	medium.	
3.9.6. Microscopes	used	in	this	work	
• Zeiss	AxioPlan	2	Microscopy	System	(Carl	Zeiss)	equipped	with	a	AxioCamHR3	camera.	
• Nikon	 Eclipse	 Ti-E	 Live	 Cell	 Imaging	 System	 (Nikon)	 equipped	 with	 a	 Nikon	 DS-Qi2	
camera	 and	 stage	 incubation	 system	 able	 to	 control	 temperature,	 humidity	 and	
percentage	of	C02.	
Post	processing	of	the	images	has	been	conducted	with	FIJI	(ImageJ)	software.		
3.10. Imaging	flow	cytometer	
5x105	EA-hy926	have	been	cultured	in	a	6-weel	cell	culture	plate	(Sarstedt)	at	37°C	with	5%	of	
CO2	in	DMEM	supplemented	with	penicillin	10U/mL	(Sigma),	streptomycin	1μg/mL	(Sigma),	L-
glutamine	2mM	(Sigma)	and	FBS	10%.	The	day	after,	cells	have	been	washed	two	times	with	
PBS	 and	 10µL	 of	 BNPs-FITC	 and	 tBNPs-FITC,	 normalized	 by	 fluorescence	 intensity	 by	
spectrophotometric	method,	have	been	incubated	with	cells	for	1h	at	37°C	with	30%	of	FBS	in	
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PBS.	Afterwards,	cells	have	been	washed	two	times	with	PBS	and	detached	with	trypsin-EDTA	
solution	(0.5g/L	porcine	trypsin	and	0.2g/L	EDTA)(Sigma)	for	5’	at	37°C.	Finally,	cells	have	been	
centrifuged	with	DMEM	medium	at	500g	for	10’	and	resuspended	in	50µL	of	2%	of	FBS	in	PBS.	
Data	 have	 been	 acquired	 with	 FlowSight	 (EMD	 Millipore,	 USA)	 with	 a	 20x	 objective	 and	
analyzed	using	IDEAS	software	version	6.0.	Cells	of	each	sample	have	been	gated	in	order	to	
select	images	with	single	cells	in	focus.	An	erode	mask	has	been	used	to	define	the	inner	part	
of	the	cell.	This	mask	removes	two	pixels	from	the	edges	of	the	starting	mask	using	bright	field	
images	of	the	cells.	The	ratio	becoming	from	the	intensity	fluorescence	between	the	inside	of	
the	cell	and	the	fluorescence	intensity	of	the	total	cell	has	been	defined	has	internalization.	
Negative	scores	represent	no	internalization,	while	cells	with	high	internalization	have	positive	
scores.	Representative	images	from	cells	populations	have	been	chosen.		
3.11. ELISA	on	EA.hy926	
3x104	Ea.hy926	cells/	well	have	been	seeded	in	a	96	well	cell	culture	plate	(Sarstedt)	in	200µL	
of	 DMEM	 medium	 supplemented	 with	 penicillin	 10U/mL	 (Sigma),	 streptomycin	 1μg/mL	
(Sigma),	L-glutamine	2mM	(Sigma)	and	FBS	10%.	After	24h,	wells	have	been	washed	twice	with	
300µL	of	PBS	and	then	fixed	with	200µL	of	1%	PFA	for	30’	at	RT.	Afterwards,	wells	have	been	
washed	two	times	with	PBS	and	then	blocked	with	200µL	of	1%	BSA	in	PBS.	2,4µL	of	BNPs-FITC	
and	 tBNPs-FITC,	normalized	by	 fluorescence	 intensity	by	spectrophotometric	method,	have	
been	 incubated	 with	 cells	 for	 1h	 at	 37°C	 with	 30%	 of	 FBS	 in	 PBS.	 In	 order	 to	 remove	
nanoparticles	which	do	not	bind	cells,	wells	have	been	washed	three	times	with	PBS.	Finally,	
the	 intensity	of	 fluorescence	has	been	detected	with	a	FLUOstar	Omega	microplate	 reader	
(BMG	Labtech)	at	520nm.		
3.12. Antigen	induced	arthritis	(AIA)	
Antigen	induced	arthritis	have	been	induced	in	male	rats	Wistar	Hannover	strain	with	a	weight	
of	120-150g.	Animals	have	been	purchased	from	Harlan	Laboratories	(San	Pietro	al	Natisone,	
Italy)	and	maintained	in	Cluster	in	BioMedicine	(CBM,	Basovizza,	Trieste)	facilities	during	the	
study	of	biodistribution,	while	animals	have	been	maintained	in	the	animal	house	of	Trieste	
(University	of	Trieste)	for	the	study	of	therapeutic	efficacy.	Experiments	have	been	conducted	
following	the	European	(86/609/EEC)	and	Italian	guidelines	(D.L	116/92)	for	the	in	vivo	animal	
experimentation	after	the	approval	by	the	Ministry	of	Education,	Universities	and	Research	
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(approval	 n°	 220/2013-B)	 and	by	 the	ethics	 committee	of	 the	University	of	 Trieste.	All	 the	
experimental	 procedures	 have	 been	 conducted	 under	 total	 anesthesia	 by	 intraperitoneal	
injection	of	Zoletil	(25mg/	Kg)	and	Xylazine	(7.5mg/	Kg).	The	immunization	has	been	performed	
with	 two	 intradermic	 injections	 (the	 second	one	 after	 one	week)	 of	 150	µg	of	methylated	
bovine	serum	albumin	(mBSA)	in	200µL	of	NaCl	0.9%	physiologic	solution	and	emulsified	with	
200µL	of	Complete	Freud	adjuvant	(CFA)	(Sigma).	After	14	days	from	the	second	immunization,	
the	inflammation	has	been	induced	by	injecting	100µg	of	mBSA	(diluted	in	100µL	of	physiologic	
solution)	 in	 the	 intraarticular	 right	 knee	 of	 the	 rats.	 The	 contralateral	 knee	 joint	 has	 been	
injected	with	the	physiologic	solution	as	the	control.		
Study	of	biodistribution	
Explore	Optix	MX	pre-clinical	optical	imaging	system	(GE	Healthcare),	equipped	with	a	pulsed	
laser	 diode	 and	 a	 time-correlated	 single-photon	 detector,	 have	 been	 used	 to	 evaluate	 the	
biodistribution	of	4.8	nmol	of	BNPs-Cy5.5	and	tBNPs-Cy5.5	diluted	in	physiologic	solution	(final	
volume	100µL)	injected	intravenously	(tail	vein)	2h	after	the	intraarticular	injection	of	mBSA.	
The	anatomical	region	to	scan	has	been	previously	shaved	to	avoid	laser	scattering	caused	by	
hair.	A	blank	image	has	been	performed	before	intravenous	injection	of	labelled	nanoparticles.	
The	animals	have	been	monitored	at	multiple	time	points	using	a	670	nm	pulsed	laser	diode	
with	a	repetition	frequency	of	80	MHz	and	a	time	resolution	of	12	light	pulses.	Fluorescence	
emission	has	been	collected	at	700	nm	and	detected	through	a	fast	photomultiplier	tube	and	
a	highly	sensitive	time-correlated	single-photon	counting	system.	Two-dimensional	scanning	
regions	of	interest	have	been	selected	through	specific	software	and	laser	power,	integration	
time	and	scan	step,	which	have	been	optimized	according	to	the	signal	emitted.	The	data	have	
been	recorded	as	temporal	point-spread	functions,	and	the	images	have	been	reconstructed	
as	 fluorescence	 intensity	 and	 fluorescence	 lifetime.	 After	 23	 days	 the	 animals	 have	 been	
euthanized	under	total	anesthesia.	Organs	have	been	analyzed	ex	vivo	for	their	fluorescence	
and	then	embedded	in	biocompatible	gelatinous	matrix	OCT	(Tissue	TEK)	and	stored	at	-80°C.	
Blood	samples	have	been	collected	for	subsequent	analysis.		
Therapeutic	efficacy	
1mg/	Kg	/day	of	MTX	and	tBNPs-MTX	diluted	in	physiologic	solution	(final	volume	of	500µL)	
have	been	administrated	intra-peritoneum	for	three	days	in	rats	developing	AIA.	The	swelling	
of	the	knees	has	been	measured	with	a	caliper.	At	the	end	of	the	study,	animals	have	been	
euthanized	under	total	anesthesia	and	the	articular	cavities	of	the	right	and	left	knees	have	
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been	washed	several	times	with	2mL	of	PBS	in	order	to	collect	synovial	fluids.	Moreover,	part	
of	the	synovial	membranes	have	been	collected	and	embedded	in	biocompatible	gelatinous	
matrix	OCT	(Tissue	TEK)	and	stored	at	-80°C,	while	the	whole	articulation	has	been	embedded	
in	paraffin	for	histological	analysis	by	hematoxylin	eosin	staining.	Blood	samples	have	been	
collected	for	subsequent	analysis.	
3.13. Collagen	induced	arthritis	(CIA)	
In	order	to	develop	CIA	model,	susceptible	male	mice	DBA/1J	strain	with	a	weight	of	13-16g	
have	been	used.	Mice	have	been	purchased	from	Harlan	Laboratories	(San	Pietro	al	Natisone,	
Italy)	and	maintained	in	the	Molecular	&	Preclinical	Imaging	Centers	(University	of	Turin,	Italy)	
during	the	study	of	biodistribution,	while	animals	have	been	maintained	in	the	animal	house	
of	Trieste	(University	of	Trieste)	for	the	study	of	therapeutic	efficacy.	Experiments	have	been	
conducted	following	the	European	(86/609/EEC)	and	Italian	guidelines	(D.L	116/92)	for	the	in	
vivo	animal	experimentation	after	the	approval	by	the	Ministry	of	Education,	Universities	and	
Research	(approval	n°	220/2013-B)	and	by	the	ethics	committee	of	the	University	of	Trieste.	
The	first	immunization	have	been	conducted	with	50µL	of	a	solution	made	of	25µL	(4mg/	mL)	
of	bovine	collagen	type	II	(Chondrex)	diluted	in	acetic	acid	10mM	and	25µL	of	CFA	(4mg/	mL	
of	M.Tuberculosis	 in	 15%	 Arlacel	 A	 (Sigma)	 and	 85%	 heavy	mineral	 oil	 (Sigma)).	 A	 second	
immunization	has	been	performed	two	weeks	later	with	the	same	concentration	of	collagen	
type	II	using	Incomplete	Freund	Adjuvant	(IFA)(without	M.	Tuberculosis).	After	20	days	mice	
show	first	signs	of	RA.	Erythema	and	swelling	characterized	the	early	stage	of	the	disease	in	
this	 model	 affecting	 randomly	 different	 paws	 with	 different	 degree	 of	 inflammation	
(polyarthritis).	Objective	evaluations	have	been	performed	three	days	per	week	establishing	a	
score	from	0	(no	arthritis)	to	4	(severe	swelling	and	ankyloses)	for	each	paw.	The	weight	of	
each	animal	has	been	recorded	three	times	per	week	in	order	to	control	side	effects.		
Study	of	biodistribution	
Mice	showing	signs	of	arthritis	have	been	enrolled	in	two	different	groups;	one	group	has	been	
injected	i.v.	with	0.5nmol	of	BNPs-Cy5.5	and	the	other	one	has	been	treated	with	0.5nmol	of	
tBNPs-Cy5.5.	 Animals	 previously	 anesthetized	 with	 Isoflurane	 have	 been	 scanned	 by	 IVIS	
Spectrum	2000	in	vivo	imaging	system	(Perkin	Elmer)	at	time	0,	1,	6,	24,	72,	96,	168	h.	At	the	
end	of	the	study,	mice	have	been	euthanized	under	total	anesthesia	in	order	to	collect	organs	
such	as	paws,	brain,	liver,	kidneys,	spleen,	lungs	and	heart.	These	organs	have	been	embedded	
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in	biocompatible	gelatinous	matrix	OCT	(Tissue	TEK)	and	stored	at	-80°C,	except	paws	which	
have	 been	 previously	 fixed	 in	 10%	neutral	 buffered	 formalin	 (BioOptica)	 for	 24h	 and	 then	
decalcifying	for	24h	with	Decalcifying	Solution-Lite	(Sigma).		
Therapeutic	efficacy	
Five	 different	 groups	 of	 mice	 have	 been	 used	 to	 assess	 the	 therapeutic	 efficacy	 of	 MTX	
encapsulated	 into	 tBNPs.	 In	particular,	one	group	have	been	treated	 i.p.	with	200µL	of	 the	
sterile	saline	solution,	one	group	with	1mg/	Kg	three	times	per	week,	one	group	with	MTX	
3mg/	Kg	per	week,	one	group	with	tBNPs-MTX	3mg/	Kg	per	week	and	one	group	with	1mg/	Kg	
per	week.	All	the	treatments	have	been	administrated	i.p.	in	a	total	volume	of	200	µL	of	sterile	
saline	 solution.	 Animals	 have	 been	 treated	 for	 25	 days	 and	 then	 euthanized	 under	 total	
anesthesia	with	Zoletil	(25mg/	Kg)	and	Xylazine	(7.5mg/	Kg).	Organs	such	as	paws,	brain,	liver,	
kidneys,	spleen,	lungs	and	heart	have	been	embedded	in	biocompatible	gelatinous	matrix	OCT	
(Tissue	TEK)	and	stored	at	-80°C,	except	paws	which	have	been	previously	fixed	in	10%	neutral	
buffered	formalin	(BioOptica)	for	24h	and	then	decalcifying	for	24h	with	Decalcifying	Solution-
Lite	(Sigma).	Blood	samples	have	been	collected	for	subsequent	analysis.	
3.14. Hematoxylin	Eosin	staining		
In	order	 to	evaluate	 the	histological	 scores	of	 the	paws	collected	 in	CIA	mice,	Hematoxylin	
Eosin	staining	have	been	performed	in	these	samples.	The	specimens	have	been	fixed	in	10%	
buffered	 formalin	 solution	and	embedded	 in	paraffin.	 Four	micrometer-thick	 sections	have	
been	dewaxed	by	immersion	in	xylene	twice	for	5’	followed	by	one	wash	in	100%	ethanol	(2’),	
one	in	96%	ethanol	(2’),	one	in	80%	ethanol	(2’)and	one	in	70%	ethanol	(2’).	Afterward,	slides	
have	 been	 rehydrated	 in	 distilled	 H2O	 for	 2’	 and	 then	 stained	 with	 Hematoxylin	 for	 40’’.	
Sections	have	been	washed	with	running	tap	water	for	1’	and	then	stained	with	Eosin	for	20’’.	
Thus,	sections	have	been	washed	with	running	tap	water	for	1’	then	they	have	been	soaked	in	
95%	ethanol	for	30’’	and	twice	in	100%	of	ethanol	for	1’.	Finally,	sections	have	been	washed	
twice	 in	 xylene	 for	 1’	 and	 mounted	 with	 Eukitt	 mounting	 medium	 (BioOptica).	 The	
histopathological	analysis	has	been	made	in	collaboration	with	Prof.	Claudio	Tripodo	and	Dr.	
Beatrice	Belmonte	at	University	of	Palermo	(Palermo,	Italy).	
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3.15. Blood	analysis	
Blood	samples	collected	from	rats	and	mice	have	been	analyzed	in	order	to	assess	the	number	
of	 red	blood	 cells,	white	 blood	 cells	 and	platelets.	 10µL	 of	 each	blood	 samples	 have	been	
analyzed	by	ABX	Micros	ES60	(Horiba	ABX	Diagnostics,	France).	Analysis	has	been	conducted	
in	collaboration	with	Prof.	Gabriele	Pozzato	at	Ospedale	Maggiore	(Trieste,	Italy).	
3.16. ELISA	mouse	anti-collagen	antibodies	
An	ELISA	test	has	been	performed	in	order	to	verify	that	all	mice	enrolled	in	the	study	develop	
an	immune	response	against	bovine	collagen	type	II.	A	solution	of	5µg/	mL	(100µL/	well)	of	
bovine	collagen	type	II	(Chondrex)	in	carbonate	buffer	0,1	M	pH	9	have	been	used	O/N	at	4°C	
as	the	coating.	The	day	after,	wells	have	been	washed	three	times	with	washing	buffer	(0,1%	
Tween	20	in	PBS)	and	blocked	1h	at	RT	with	200µL	of	2%	skim	milk	in	PBS.	Then,	wells	have	
been	washed	three	times	with	washing	buffer	and	serum	samples,	previously	diluted	1:2000	
in	diluent	buffer	(0,05%	Tween	20	and	0,1%	skim	milk	in	PBS),	have	been	placed	in	each	well	
in	a	final	volume	of	100µL.	Other	three	washes	have	been	done	with	washing	buffer	and	then	
the	secondary	antibody	goat	anti-mouse	AP	(Sigma)	has	been	diluted	1:2000	 in	 the	diluent	
buffer	and	incubated	for	1h	at	RT.	Finally,	three	washes	have	been	done	with	washing	buffer	
and	the	alkaline	phosphatase	substrate	p-nitrophenylphosphate	(pNPP)	(Sigma)	has	been	used	
1mg/	mL	in	glycine	buffer	(0,1M	Glycine,	0,1mM	MgCl2	and	0,1mM	ZnCl2,	pH	9.6)	in	order	to	
develop	 the	 reaction.	 The	plate	 has	 been	measured	 at	 405	nm	by	 Infinite	M200	Pro	plate	
reader	(Tecan).	
3.17. ELISA	rat	anti-mBSA	antibodies	
In	 order	 to	 verify	 that	 rats	 enrolled	 in	 the	 study	 developed	 an	 immune	 response	 against	
methylated	bovine	serum	albumin	(mBSA)	an	ELISA	test	has	been	used.	A	solution	of	5µg/	mL	
(100µL/	well)	of	mBSA	(Sigma)	in	carbonate	buffer	0,1	M	pH	9	have	been	used	O/N	at	4°C	as	
the	coating.	The	day	after,	wells	have	been	washed	 three	 times	with	washing	buffer	 (0,1%	
Tween	20	in	PBS)	and	blocked	1h	at	RT	with	200µL	of	2%	skim	milk	in	PBS.	Then,	wells	have	
been	washed	three	times	with	washing	buffer	and	serum	samples,	previously	diluted	1:2000	
in	the	diluent	buffer	(0,05%	Tween	20	and	0,1%	skim	milk	in	PBS),	have	been	placed	in	each	
well	in	a	final	volume	of	100µL.	Three	washes	have	been	done	with	washing	buffer	and	then	
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the	secondary	antibody	rabbit	anti-rat	biotin	(Sigma)	has	been	diluted	1:4000	in	the	diluent	
buffer	and	 incubated	 for	1h	at	RT.	After	 three	more	washes	with	wash	buffer,	 streptavidin	
conjugated	 to	 horseradish	 peroxidase	 (HRP)(Sigma)	 diluted	 1:2000	 in	 the	 diluent	 has	 been	
incubated	for	30’	at	RT.	Finally,	three	washes	have	been	done	with	washing	buffer	and	the	
peroxidase	substrate	3,3ʹ,5,5ʹ-Tetramethylbenzidine	(TMB)(Sigma)	has	been	used	(100µL)	to	
develop	the	reaction,	which	has	stopped	with	100µL	of	H2SO4	1M	(Sigma).		The	plate	has	been	
measured	at	450	nm	by	Infinite	M200	Pro	plate	reader	(Tecan).	
3.18. Number	of	polymorphonuclear	(PMN)	leukocytes.	
In	 order	 to	 measure	 the	 number	 of	 PMN	 leukocytes	 in	 synovial	 fluids	 of	 AIA	 rats,	 the	
myeloperoxidase	activity	has	been	measured.	For	 this	purpose,	a	 standard	curve	with	 rat’s	
PMN	with	 known	 concentration	 (500000cells/mL)	 has	 been	 prepared.	Hundred	μL	 of	 each	
sample	has	been	loaded	in	well	of	a	96	well	plate	polystyrene	flat	bottom	(Costar)	and	then,	
100	μL	of	peroxidase	substrate	TMB	(Sigma)	has	been	added	to	each	well.	The	colorimetric	
reaction	 has	 been	 stopped	 with	 100μL	 of	 H2SO4	 1M	 (Sigma).	 Finally,	 the	 plate	 has	 been	
measured	by	the	spectrophotometric	reader	(ELISA	reader,	Anthos	2020)	at	450nm.	
3.19. Multiplex	ELISA	
Cytokines	and	chemokines	have	been	quantified	using	the	Bio-Plex	Pro	Mouse	Cytokines	23-
plex	Assay	(BioRad),	according	to	the	manufacturer’s	instructions.	Serum	samples	of	each	mice	
group	have	been	pooled	and	then	12,5µL	has	been	analysed	in	triplicate.	In	particular,	IL-1a,	
IL-1b,	IL-2,	IL-3,	IL-4,	IL-5,	IL-6,	IL-9,	IL-10,	IL-12	(p40),	IL-13,	IL-17A,	KC,	MCP-1,	MIP-1a,	MIP-
1b,	Eotaxin,	G-CSF,	GM-CSF,	 INF-g,	RANTES	and	TNF-a	have	been	analysed	by	this	method.	
Data	have	been	acquired	with	Bio-Plex	200	reader	(BioRad)	and	analysed	with	the	software	
Bio-Plex	Manager	to	calculate	results	as	concentration	in	pg/	mL.	
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4. Results	and	discussion	
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4.1. Design	and	characterization	of	biodegradable	nanoparticles	
4.1.1. Design	and	characterization	of	the	targeting	molecule	
The	 targeting	 synovial	 peptide,	 used	 in	 this	 study,	 is	 made	 of	 9	 aminoacids	 (CKSTHDRLC)	
containing	two	flanking	cysteines	(Figure	9b),	which	constrain	the	peptide	in	a	circular	shape	
improving	the	binding	of	the	consensus	motif	(aminoacids	DRL)	to	its	counterpart	(Lee	et	al.	
2002).	Due	to	the	small	size	of	the	synovial	peptide,	we	avoided	to	directly	link	the	peptide	on	
the	nanoparticles	because	polymers,	 in	particular,	PEG	exposed	on	particles’	 surface,	could	
mask	the	exposure	of	the	peptide.	For	this	reason,	the	synovial	peptide	has	been	fused	to	the	
Fc	of	a	ScFv-Fc	(Figure	9	A),	which	acts	as	a	spacer	able	to	display	the	peptide	far	from	the	
nanoparticles’	surface.	The	sequence	coding	for	the	targeting	molecule	has	been	cloned	in	the	
vector	pcDNA3.1/Hygro+;	 it	 contains	 the	 sequence	of	 a	 non-correlated	 ScFv,	 the	 sequence	
coding	 for	 the	 hinge-CH2-CH3	 of	 the	 rat	 IgG2b,	 the	 sequence	 for	 the	 SV5	 tag	 (used	 for	
detection)	and	the	sequence	for	the	synovial	peptide.	In	order	to	obtain	a	stable	clone	able	to	
produce	high	amount	of	the	targeting	molecule,	the	vector	coding	for	its	sequence,	previously	
checked	 by	 DNA	 sequencing,	 has	 been	 transfected	 in	mammalian	 cells	 of	 Chines	 Hamster	
Ovary	(CHO).	The	3D	structure	of	the	targeting	molecule	has	been	predicted	through	the	web	
server	Phyre2	(Kelley	et	al.	2015),	aiming	to	understand	the	peptide’s	orientation	in	the	3D	
space	 and	whether	 the	 peptide	 could	 be	masked	 during	 the	 folding	 of	 the	 final	 structure	
(Figure	 9	 C).	 The	 prediction	 is	 performed	 through	 a	 combination	 of	 multiple	 template	
modelling	 and	 ab-initio	 folding	 simulation.	 The	 94%	 of	 residues	 of	 the	 final	 3D	 structure	
reported	 in	 the	 figure	9	C	have	been	modelled	with	a	confidence	higher	 than	90%	and	the	
peptide	(Figure	9	C	red	box)	appears	available	to	interact	with	its	counterpart.		
The	 targeting	 molecules	 have	 been	 produced	 and	 purified	 by	 affinity	 chromatography	
exploiting	the	binding	between	the	Fc	and	the	protein	A.	The	molecular	weight	and	the	quality	
of	 the	 protein	 produced	 and	 purified	 have	 been	 assessed	 by	western	 blot;	 as	 expected	 in	
reducing	conditions,	the	molecular	weight	of	the	monomers	have	been	determined	as	62kDa	
and	low	amount	of	aggregated	or	degraded	proteins	have	been	detected	(Figure	9	D).		
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the	inflamed	synovia.	Our	finding	is	also	supported	by	Lee	et	al.	who	have	isolated	the	peptide	
proving	its	ability	to	bind	the	microvasculature	of	the	RA	synovial	tissue	(Lee	et	al.	2002).	For	
these	reasons,	subsequent	in	vitro	tests	to	study	and	characterize	targeted-nanoparticles	will	
be	conducted	on	a	endothelial	cell	line	EA.hy926.	
In	 order	 to	 better	 identify	 the	 protein	 bound	 by	 the	 targeting	 molecule,	 an	 immuno-
precipitation	followed	by	mass	spectrometry	analysis	has	been	conducted;	in	particular,	the	
targeting	 molecules	 have	 been	 coupled	 to	 Sepharose	 beads	 and	 a	 lysate	 of	 EA.hy	 926	
endothelial	cell	 line	has	been	used	as	 loading	material.	A	ScFv-Fc	fused	with	a	RGD	peptide	
coupled	to	Sepharose	has	been	used	as	the	control.	Several	proteins	differentially	bound	by	
the	 synovial	 peptide	 have	 been	 identified,	 however,	 any	 of	 them	 could	 be	 reasonably	
associated	with	a	surface	protein	of	endothelial	cells.	Indeed,	most	of	the	proteins	identified	
comes	from	the	inner	part	of	the	cells,	so	are	in	contrast	with	our	immunofluorescence	findings	
and	 literature.	 Probably,	 the	 method	 should	 be	 improved	 for	 the	 enrichment	 of	 surface	
proteins.		
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fluorescence)	in	colocalization	with	the	CD34	(red	fluorescence).	Nuclei	are	stained	with	Dapi.	Scale	bar	20	µm.	
4.1.2. Design	and	characterization	of	targeted	nanoparticles	for	
rheumatoid	arthritis	
According	 to	 the	 recent	 literature,	 already	 discussed	 in	 the	 introduction	 of	 this	 work,	
nanoparticles	can	be	designed	in	order	to	increase	specificity	for	a	target	tissue	reducing	doses	
of	 drugs	 and	 their	 consequent	 toxicity.	 Following	 the	 rationale	 of	 the	 project,	 core-shell	
biodegradable	 polymeric	 nanoparticles	 made	 of	 COOH-poly(ethylene	 glycol)-b-polylactide	
(PEG-b-PLA)	 and	Poly(caprolactone)-COOH	 (PCL)	were	 produced	 in	 collaboration	with	 Prof.	
Luis	 Núñez	 founder	 of	 BioTarget,	 a	 company	 based	 in	 Chicago.	 Due	 to	 their	 patented	
technology	and	methodology	(number	US20080187487	A1)	based	on	a	electrohydrodynamic	
coaxial	 two-capillary	 system,	 polymeric	 nanoparticles	 can	 be	 customized;	 the	 shell	 can	 be	
produced	with	different	polymers	and	later	functionalized	with	targeting	molecules	using	N-
Hydroxysuccinimide	(NHS)	as	coupling	agent;	the	core	can	be	loaded	with	different	drugs	and	
diagnostic	tracers.	Moreover,	the	dimension	of	the	nanoparticles	can	be	controlled	by	varying	
the	 flow	 speed	 inside	 the	 capillaries.	 Four	 different	 kinds	 of	 biodegradable	 nanoparticles	
(BNPs)	were	produced	to	develop	this	project	(Figure	11).	In	particular:	BNPs	with	empty	core	
and	the	shell	made	of	PEG-b-PLA	and	PCL,	targeted	BNPs	(tBNPs)	which	are	BNPs	conjugated	
with	the	targeting	molecule,	BNPs	loaded	with	MTX	(BNPs-MTX)	and	tBNPs	loaded	with	MTX	
(tBNPs-MTX).		
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position	of	free	amino	groups	available	for	the	conjugation.	To	this	aim	a	detailed	3D	structure	
have	 been	 performed	 showing	 the	 ScFv-Fc-targeting	 molecule	 folding	 in	 its	 dimeric	 form	
(Figure	12	A).	The	ScFv	fragment	and	the	Fc	have	been	modelled	with	high	reliability,	while	the	
linker	between	the	VL	and	VH	has	not	been	modelled	because	no	similar	crystal	structures	
were	present	in	literature.	The	hinge	region	has	been	modelled	with	medium	reliability	and	
due	to	the	presence	of	four	cysteines,	same	disulphide	bridges	may	be	formed.	Moreover,	by	
definition,	the	hinge	region	 is	extremely	flexible	and	the	orientation	of	the	Fc	and	the	ScFv	
could	be	different	from	this	prediction.	However,	the	tag	SV5	has	been	modelled	with	medium	
reliability	due	to	the	presence	of	a	similar	crystal	structure.	This	information	gives	confidence	
regarding	the	orientation	of	targeting	peptide,	which	is	fused	to	the	tag.	Indeed,	it	is	possible	
to	speculate	that	the	targeting	peptide	protrudes	in	the	space	avoiding	unwanted	interaction	
with	parts	of	the	own	molecule.	However,	the	synovial	peptide	has	been	modelled	with	low	
reliability	based	on	a	crystal	structure	fragment	of	the	E3	ubiquitin-protein	ligase.	Despite	the	
low	 reliability,	 5	 residues	 out	 of	 9	 are	 identical	 to	 those	 of	 E3	 ubiquitin-protein	 ligase,	 in	
particular	 the	 identical	 residues	 are	 located	 in	 both	 extremities	 of	 the	 sequence,	 which	
contains	the	two	flanking	cysteines	responsible	for	the	circularization	of	the	peptide.	Thus,	it	
is	highly	truthful	that	the	targeting	peptide	assumes	a	circular	shape	excluding	other	possible	
folds.	To	conclude,	 free	amino	groups	available	on	the	surface	of	 the	target	molecule	have	
been	highlighted	(Figure	12	C).	 In	particular,	amine	groups	of	Lys	residues	are	presented	 in	
purple,	while	 the	guanidinium	group	of	Arg	 residues	 are	 shown	 in	pink.	 In	 the	3D	models,	
reported	from	different	viewpoints,	is	possible	to	appreciate	many	free	amino	groups	spreads	
all	 over	 the	 surface	 of	 the	 targeting	molecule.	 Thus,	 is	 not	 possible	 to	 predict	 the	 correct	
orientation,	but	the	higher	number	of	free	amino	groups	are	located	in	the	Fc	of	the	molecule	
with	a	higher	availability	for	the	binding.	Considering	this	assumption	correct,	it	is	reasonable	
that	only	one	monomer	of	the	molecule	is	involved	in	the	binding	with	the	polymers	of	the	
nanoparticles,	 therefore	 the	 other	 monomer	 is	 available	 to	 display	 the	 targeting	 peptide	
(Figure	11).			
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fundamental	 to	 transfer	 this	 technology	 in	a	 clinical	 context.	The	negative	charge	prevents	
undesired	 interaction	 with	 the	 MPS	 and	 shows	 low	 toxicity	 than	 positively	 charged	
nanoparticles.	Usually,	the	charge	is	expressed	as	Zeta	potential	(ζ),	which	reflex	the	charge	on	
the	nanoparticles’	surface.	The	diameter	plays	an	important	role	in	the	clearance,	circulation	
time	 and	 internalization	mechanisms.	 To	 this	 aim,	 nanoparticles	with	 a	 diameter	 <	 200nm	
should	guarantee	a	good	circulation	time.	Finally,	the	PDI	is	an	important	parameter,	which	
describes	the	heterogeneity	of	the	size	distribution	of	molecules	or	particles	in	a	solution.	The	
dispersity	index	value	ranges	from	0	to	1,	where	values	close	to	0	are	considered	monodisperse	
while	values	close	to	1	are	considered	polydisperse.	After	the	production,	the	nanoparticles	
have	been	characterized	by	dynamic	light	scattering	(DLS),	which	measures	the	PDI,	the	Zeta	
potential,	and	the	hydrodynamic	diameter.	The	DLS	data	confirm	an	average	hydrodynamic	
diameter	of	150nm,	an	average	PDI	of	0.3	and	a	slight	negative	charge	between	-6mV	and	-
9.6mV	 (Figure	 13	 A).	 Data	 obtained	 by	 DLS	 have	 been	 confirmed	 by	 nanoparticle	 tracking	
analysis	(NTA),	a	technique	similar	to	the	DLS,	which	give	us	additional	information	regarding	
the	number	of	 nanoparticles	 in	 solution	 (Figure	 13	B).	 Indeed,	 through	 this	 technique,	 the	
average	 diameter	 has	 been	 170nm	 while	 the	 PDI	 about	 0.2.	 Concerning	 the	 number	 of	
nanoparticles	in	solution,	the	average	concentration	has	been	3	x	1010particles/	mL.	Moreover,	
information	 regarding	 the	morphology	 and	 the	 state	 of	 aggregation	 has	 been	 collected	 by	
transmission	 electron	 microscopy	 (TEM)	 (Figure	 13,	 C	 and	 D)	 and	 scanning	 transmission	
electron	microscopy	(STEM)	(Figure	13,	E	and	F).	
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BNPs	and	tBNPs,	minimally	influence	the	viability	of	the	cells,	showing	an	average	viability	of	
78%	compared	to	not	treated	cells.	Despite	the	statistical	difference	reported	between	not	
treated	cells	and	cells	treated	with	empty	BNPs	and	tBNPs,	a	viability	of	80%	should	not	be	
considered	an	index	of	toxicity,	since	this	result	depends	on	the	cell	 line	and	the	conditions	
used	for	in	vitro	tests.	Indeed,	a	98%	of	living	cells	have	been	reported	using	same	empty	BNPs	
and	tBNPs	and	same	experimental	condition,	but	using	a	different	cell	line	such	as	MDA231	or	
other	cell	lines	(data	not	shown).	Instead,	same	volumes	of	BNPs-MTX	and	tBNPs-MTX	showed	
a	decreased	percentage	of	living	cells	compared	to	cells	treated	with	free	MTX	(yellow	bars).	
As	 expected,	 MTX	 encapsulated	 into	 nanoparticles	 had	 a	 superior	 cytotoxicity	 against	
endothelial	 cells,	 proving	 that	nanoparticles	 are	 able	 to	enter	 into	 cells	 delivering	 a	higher	
amount	of	MTX.		
Once	nanoparticles	have	been	characterized	by	their	physicochemical	properties	and	for	their	
biocompatibility	it	is	important	to	study	the	pharmacokinetic	release	of	the	encapsulated	drug.	
To	 this	 aim,	BNPs-MTX	have	been	dialyzed	 in	PBS	pH	7.4	at	37°	 in	 slight	 agitation	and	 the	
released	MTX	have	been	measured	by	UV-Vis	spectrophotometer	at	310nm.	The	drug	has	been	
measured	for	24	hours	and	compared	with	the	release	of	MTX	non-encapsulated	(Figure	14	B).	
As	shown	in	the	graph,	more	than	60%	of	non-encapsulated	MTX	comes	out	from	the	dialysis	
tube	in	five	hours,	while	40%	of	MTX	have	been	released	from	tBNPs.	However,	after	the	initial	
release,	 a	 plateau	 is	 reached	 after	 5	 hours	 demonstrating	 that	 50%	 of	MTX	 is	 still	 stable	
encapsulated	 in	 the	 core	 of	 the	 nanoparticles	 for	 at	 least	 24h.	 This	 result	 suggests	 that	
nanoparticles,	once	injected	and	reached	the	target,	may	release	50%	of	the	drug	over	a	period	
longer	 than	 24h.	 The	 initial	 fast	 release	 is	 known	 as	 “burst	 release”,	 a	 phenomenon	
characterizing	 drug	 delivery	 systems.	 Indeed,	 numbers	 of	 papers	 have	 been	 published	 to	
explain	 and	 overcome	 negative	 effects	 of	 this	 initial	 release	 (Huang	 &	 Brazel	 2001).	Main	
reasons	concerning	the	burst	have	been	associated	with	the	shape	and	pore	sizes	of	polymeric	
nanoparticles	as	well	as	to	the	drug	low	molecular	weight.	Moreover,	during	the	process	of	the	
drug	encapsulation,	part	of	the	drug	entrapped	in	the	shell	could	be	quickly	released	causing	
the	burst	effect.		
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fluorescence)	 if	 compared	 with	 the	 healthy	 synovial	 tissue.	 Later,	 nanoparticles	 coupled	
with/out	the	target	molecules	and	labelled	with	FITC	have	been	incubated	with	inflamed	and	
healthy	 synovial	 tissue	 (Figure	 15	 B).	 A	 higher	 number	 of	 green	 spots,	 in	 other	 words	
nanoparticles,	 have	 been	 detected	 on	 the	 inflamed	 synovial	 tissue	 incubated	 with	 tBNPs	
compared	with	the	control	tissue.	In	addition,	very	few	spots	have	been	found	on	the	staining	
performed	with	untargeted	BNPs	in	both	inflamed	and	healthy	synovial	tissues.	Most	of	these	
spots	have	been	localized	outside	the	tissues,	probably	because	of	a	nonspecific	binding	of	the	
BNPs.	 As	 predicted	 from	 the	 3D	molecular	models,	 performed	 during	 the	 design	 of	 target	
molecule	and	the	tBNPs,	these	experiments	proved	the	functionality	of	the	targeting	peptide	
once	fused	to	the	ScFv-Fc	and	also	when	the	targeting	molecule	is	coupled	with	nanoparticles.		
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As	already	shown,	the	targeting	molecule	is	able	to	preferentially	bind	cells	of	the	inflamed	
synovial	tissue.	Moreover,	once	the	target	molecule	is	coupled	with	the	nanoparticles,	these,	
in	turn,	are	able	to	target	the	inflamed	synovia.	However,	immunofluorescence	staining	with	
nanoparticles	is	troublesome	and	results	are	usually	qualitative.	Indeed,	this	method	requires	
the	use	of	 fixative	solution	and	 the	use	of	detergents,	which	can	be	 incompatible	with	 the	
stability	of	the	nanoparticles.	Thus,	in	order	to	improve	our	knowledge	about	the	targeting	and	
the	 internalization	 into	 endothelial	 cells,	 in	 vitro	 experiments	 have	 been	 conducted	 with	
EA.hy926	 trying	 to	 overcome	 methodological	 problems.	 First,	 in	 order	 to	 investigate	 the	
binding	and	internalization,	living	EA.hy926	cells	have	been	incubate	for	1h	with	both	BNPs-
Cy5.5	and	tBNPs-Cy5.5.	The	figure	16	A	clearly	shows	the	binding	of	both	kinds	of	nanoparticles	
to	EA.hy926,	nevertheless	it	is	not	possible	to	understand	whether	the	nanoparticles	are	inside	
the	cells	or	if	they	are	only	in	contact	with	the	cellular	membrane.	For	this	reason,	in	order	to	
have	 quantitative	 data,	 an	 ELISA	 test	 has	 been	 performed	 on	 living	 EA.hy926.	 Results	 are	
shown	in	the	figure	16	B.	It	is	evident	that	tBNPs-FITC	are	able	to	bind	endothelial	cells	more	
than	BNPs	because	of	the	targeting	molecule,	which	is	capable	of	a	stable	binding.	 Instead,	
BNPs	bind	cells	by	chance	using	their	charge	or	possible	hydrophobic	interaction.	However,	by	
ELISA	test	it	is	not	possible	to	discriminate	between	those	nanoparticles	that	are	simply	bound	
to	the	cell	surface	and	those	that	are	internalized.	Thus,	a	powerful	instrument	called	AMNIS,	
combining	speed	and	sample	size	of	flow	cytometry	and	with	the	resolution	and	sensitivity	of	
microscopy	has	been	used	to	quantify	the	number	of	cells	bound	by	tBNPs-FITC	and	BNPs-FITC.	
Moreover,	 this	 method	 allows	 to	 quantify	 the	 percentage	 of	 internalised	 nanoparticles.	
EA.hy926	 cells	 have	 been	 incubated	 for	 2h	with	 both	 BNPs-FITC	 and	 tBNPs-FITC	 and	 then	
analysed	by	AMNIS	(Figure	16	C).	The	gate	has	been	applied	for	cells	positive	for	FITC	in	order	
to	quantify	cells	bound	by	nanoparticles.	About	2.7	%	of	cells	incubate	with	tBNPs-FITC	have	
been	detected	positive	for	FITC	compare	with	0,7%	of	cells	incubated	with	BNPs-FITC.	This	data	
confirms	 that	 tBNPs,	 due	 to	 the	 target	mechanism,	 are	 able	 to	 improve	 the	 binding	 with	
endothelial	cells.	During	the	analysis,	cells	positive	for	FITC,	so	bound	by	nanoparticles,	have	
been	individually	photographed	with	a	microscope	both	in	bright	field	and	fluorescence.	Then,	
the	images	have	been	processed	to	discriminate	if	the	nanoparticles	are	inside	or	outside	the	
cells;	a	dedicated	software	creates	a	mask	of	the	cell	shape	using	the	bright	field	and	then,	
merging	the	fluorescence	image,	it	defines	the	localization	of	the	nanoparticles.	The	figure	16	
D	shows	representative	images	of	tBNPs-FITC	inside	a	cell	and	BNPs-FITC	in	contact	with	the	
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cell	 membrane.	 Graphs	 reported	 in	 the	 figure	 16	 E,	 F	 and	 G	 summarize	 respectively	 data	
regarding	the	percentage	of	cells	positive	for	FITC,	the	percentage	of	internalization,	which	is	
the	same	for	both	tBNPs	and	BNPs,	and	the	final	percentage	of	cells	internalizing	particles.	It	
is	possible	to	conclude	that	the	percentage	of	internalization	does	not	change	between	the	
BNPs	 and	 the	 tBNPs,	 however	 because	 the	 targeting	molecule	 increases	 tBNPs	 binding,	 as	
consequence,	percentage	of	tBNPs	internalised	is	higher.	
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at	 525nm	 by	 ELISA	 plate	 reader.	 (C)	 EA.hy926	 cells	 incubated	with	 BNPs-FITC	 and	 tBNPs-FITC	 have	 been	 gated	 for	 their	
fluorescence	using	as	control	not-treated	cells.	The	first	plot	shows	in	focus	objects	described	with	the	“aspect	ratio”	(Y	axis)	
defined	as	the	minor	axis	divided	by	the	major	axis	and	describes	how	round	an	object	is,	while	the	X	axis	defines	the	“Area”	
in	µm2.	In	the	second	plot,	the	Y	axis	shows	the	“max	pixel”,	which	measure	the	largest	value	of	the	background-subtracted	
pixels	contained	in	in	the	input	mask,	while	the	X	axis	shows	the	intensity	of	fluorescence.	The	third	plot	shows	the	“frequency”	
of	particles	internalized	on	the	Y	axis	while	on	the	X	axis	the	“internalization”	is	defined	as	the	ratio	of	the	intensity	inside	the	
cell	to	the	intensity	of	the	entire	cell	using	specific	masks	to	define	the	inner	part.	Finally,	pixels	on	the	edge	of	the	main	mask	
have	been	removed	by	the	“erode	mask”.	The	higher	score	represents	a	greater	concentration	of	intensity	inside	the	cell.	Cells	
with	 internalized	nanoparticles	 typically	 have	positive	 scores	while	 cells	with	 no	 internalization	have	negative	 scores.	 (D)	
Representative	images	acquired	during	the	analysis	of	two	cells	positive	for	FITC,	one	with	tBNPs-FITC	and	one	with	BNPs-
FITC.	Scale	bar	20µm.	(E)	The	graph	summarises	percentage	of	cells	positive	for	FITC	when	incubated	with	BNPs-FITC	or	tBNPs-
FITC	while	 (F)	 reports	 the	 percentage	 of	 internalization.	 (G)	 The	 percentage	 of	 cells	 with	 internalized	 particles	 has	 been	
obtained	applying	the	%	of	internalization	on	the	%	of	bound	cells.		
4.2.2. In	vivo	biodistribution	of	BNPs	and	tBNPs	in	a	AIA	rat	model	
In	the	paragraph	4.2.1	it	has	been	demonstrated	that	the	targeting	molecule	and	the	tBNPs	
were	able	to	preferentially	bind	inflamed	synovial	tissue	in	vitro.	In	order	to	confirm	this	result	
in	vivo,	4.8	nM	of	Cy5.5	labelled	on	tBNPs	and	BNPs	were	injected,	through	the	tail	vein,	in	rats	
developing	inflammation	in	the	right	knees.	This	model	of	monoarthritis,	called	AIA,	is	a	useful,	
easy	and	quick	model	to	study	biodistribution	of	new	therapeutic	and	diagnostic	compounds	
for	the	management	of	RA.	After	three	days	from	the	induction	of	the	inflammation	in	the	right	
knee,	 nanoparticles	 have	 been	 injected	 and	 then	 followed	 for	 23	 days	 (Figure	 17	 A).	 The	
animals,	 analysed	 following	 Cy5.5	 by	 near	 infrared	 optical	 imaging,	 clearly	 show	 a	 higher	
accumulation	of	fluorescence	in	the	right	knee	of	the	animals	receiving	tBNPs-Cy5.5	compared	
to	 the	 contralateral	 knee	 (not	 inflamed)	 or	 animals	 treated	 with	 BNPs-Cy5.5.	 Plotting	 the	
fluorescence	data	from	figure	A,	it	is	possible	to	obtain	the	graph	of	the	figure	17	B.	The	graph	
highlights	an	improved	accumulation	of	tBNPs-Cy5.5	in	the	right	inflamed	knees,	reaching	the	
maximum	after	7/8	days.	In	order	to	assess	the	accumulation	in	other	tissues,	at	the	end	of	
the	study,	the	fluorescence	has	been	measured	ex	vivo	in	the	main	organs	such	as	liver,	spleen,	
lungs,	kidneys,	brain,	heart	and	paws.	Indeed,	from	the	picture	17	C,	it	is	possible	to	appreciate	
the	higher	accumulation	of	nanoparticles	into	the	liver,	followed	by	kidneys.	It	is	interesting	to	
notice	that	the	target	mechanisms	coupled	on	tBNPs	did	not	 influence	the	accumulation	 in	
these	organs.	Moreover,	the	higher	fluorescence	intensity	detected	in	the	liver	suggests	that	
these	nanoparticles,	as	already	studied	by	our	group,	due	to	their	physicochemical	features	
are	 mainly	 eliminated	 through	 the	 bile	 in	 the	 gut	 and	 finally	 removed	 with	 the	 faeces.	
Fluorescence	data	detected	on	the	knees	have	been	correlated	with	their	swelling	(Figure	17	
E),	which	is	the	main	inflammatory	parameter	to	evaluate	AIA.	It	is	important	to	notice	that	
both	tBNP-Cy5.5	and	BNPs-Cy5.5	groups	of	animals	had	the	same	swelling	for	the	 inflamed	
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in	the	joints.	Once	animals,	in	this	case	mice,	developed	the	disease,	they	were	enrolled	in	two	
groups,	receiving	tBNPs	or	BNPs.	Mice	have	been	scanned	for	7	days	and	images	of	the	limbs	
of	two	representative	mice	are	shown	in	the	figure	18	A.	Moreover,	the	arthritis	score,	ranging	
from	0	(no	arthritis)	to	4	(worst	arthritis)	and	reflecting	the	severity	of	the	disease,	have	been	
assessed	 in	order	 to	associate	 the	 fluorescence	with	disease	progression.	 It	 is	 important	 to	
notice	 from	 figure	 18	 B	 that	 paws	 with	 the	 same	 score	 show	 a	 different	 intensity	 of	
fluorescence	and	the	highest	have	been	detected	in	the	paw	of	a	mouse	treated	with	tBNPs-
Cy5.5.	In	fact,	graphs	of	the	figure	18	C	show	a	higher	fluorescence	intensity	at	both	score	0	
and	3.	Importantly,	the	statistical	significance	has	been	reached	in	the	first	24h.	This	result,	
however,	diverges	from	the	biodistribution	obtained	in	AIA,	where	the	highest	fluorescence	
difference	has	been	reached	after	1	week.	Nevertheless,	these	two	RA	models	are	based	on	
two	different	pathogenesis	processes.	Indeed,	the	AIA	is	an	acute	model	and	the	inflammation	
increase	 together	 with	 the	 formation	 of	 new	 vessels,	 supporting	 the	 data	 showing	 a	
progressive	accumulation	during	the	first	week.	Instead,	the	CIA	is	a	chronic	model	of	RA	where	
the	 inflammation	and	the	new	blood	vessels	are	already	established	before	the	study,	thus	
tBNPs	are	able	to	accumulate	immediately	after	their	injection.	Of	interest	is	the	trend	showed	
by	the	tBNPs-Cy5.5	fluorescence	(figure	18	C),	indeed	the	initial	fluorescence	peak,	due	to	the	
nanoparticles	 injected	in	the	tail	vein,	 is	followed	by	a	decrease	fluorescence	intensity	(6h),	
probably	 due	 to	 the	 clearance	 of	 the	 excess	 of	 nanoparticles.	 Finally,	 the	 fluorescence	
increased	 again	 after	 24h	 in	 mice	 receiving	 tBNPs-Cy5.5	 only,	 proving	 their	 accumulation	
compared	with	BNPs.		
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Balthasar	2003).	Considering	this	information,	one	group	of	arthritic	mice	has	been	treated	i.p.	
with	saline	solution	(as	negative	control);	another	group	has	been	treated	with	1mg/Kg	of	free	
MTX	 three	 times	 per	 week	 and	 represents	 the	 positive	 control,	 adapting	 data	 present	 in	
literature	 (Lange	 2005)(Jung	 et	 al.	 2015).	 Because	 nanoparticles	 persist	 in	 the	 inflamed	
synovium	for	about	a	week,	a	group	of	mice	has	been	treated	with	an	equivalent	dose	of	tBNPs-
MTX,	in	particular	not	1mg/Kg	three	times	per	week	but	a	single	dose	of	3mg	/Kg	per	week.	As	
shown	in	the	graph	20	A,	this	dose	of	tBNPs-MTX	(continuous	blue	line)	showed	a	decreased	
arthritic	score,	compared	to	control	animals	(red	line),	proving	its	efficacy.	This	result	is	in	line	
with	the	therapeutic	effect	provided	by	the	treatment	with	the	free	drug.	
One	of	 the	primary	objectives	of	 the	project	 is	 to	 demonstrate	 that	 the	 selective	delivery,	
which	increases	the	concentration	of	nanoparticles	and	MTX	in	the	inflamed	joints,	may	allow	
a	dose	reduction	compared	to	a	standard	treatment.	To	this	aim,	another	group	of	mice	has	
been	treated	with	a	lower	dose	of	tBNPs-MTX	equivalent	to	1mg/Kg	per	week	(dotted	blue	
line).	Even	with	a	lower	dose,	the	targeting	mechanism	guarantees	therapeutic	efficacy	over	
the	free	drug.		
As	expected,	the	group	of	mice	treated	with	a	single	injection	of	3mg/Kg	of	free	MTX	(dotted	
black	line)	did	not	show	any	efficacy	compared	to	control	group,	confirming	that	MTX,	due	to	
its	fast	clearance,	cannot	be	administrated	once	per	week.		
At	 the	 end	 of	 the	 study,	 mice	 have	 been	 euthanized	 and	 paws	 have	 been	 collected	 for	
subsequent	analysis.	Indeed,	the	therapeutic	efficacy	of	the	tBNPs-MTX	compared	to	control	
and	free	MTX	have	been	validated	by	histological	analyses	(Figure	20	B).	These	images	were	
then	 analysed	 and	 histological	 scores	 (Figure	 20	 C)	 show	 reduction	 of	 the	 cartilage	 and	
subchondral	bone	infiltration	(Figure	20	E,	D),	as	well	as	a	reduction	in	the	stromal	proliferation	
(Figure	20	G)	in	mice	treated	with	the	effective	doses	of	tBNPs-MTX	and	free	MTX.	
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(continuous	blue	line);	tBNPs-MTX	1mg/	Kg	one	time	per	week	(dotted	blue	line).	The	scores	have	been	reported	as	the	mean	
of	the	sum	of	the	scores	±	SEM	assessed	for	each	paw	of	the	mouse.	The	score	values	range	from	0	(no	arthritis)	to	4	(highly	
inflamed,	swollen	or	ankylosed	paw).	Statistical	significance	has	been	assessed	by	Two-way	ANOVA	test.	P	≤	0.05	=	*;	P	≤	0.01	
=	**;	P	≤	0.001	=	***;	P	≤	0.0001	=	****.	(B)	Histological	images	representative	of	each	group	of	mice	treated	in	this	study.	An	
additional	 image	of	a	healthy	paw	was	added	to	the	panel	as	the	negative	control.	The	group	treated	with	saline	solution	
shows	the	worst	profile	characterized	by	a	hyperplastic	synovial	tissue,	huge	infiltration	of	leukocytes	and	loss	of	cartilage	and	
bone	structure.	(C)	Histological	total	score	reported	as	the	mean	±	SD	of	the	scores	assigned	for	each	mouse	of	the	study.	The	
score	is	the	result	of	scores	assigned	for	7	different	parameters	such	as	subchondral	bone	infiltration	(D),	cartilage	infiltration	
(E),	fibrinoid	necrosis	(F),	stromal	proliferation	(G),	lymphoid	infiltration	(H),	granulocytic	infiltration	(I)	and	synovial	epithelial	
proliferation	(J).	Statistical	significance	has	been	assessed	by	unpaired	parametric	t-test.	P	≤	0.05	=	*	
4.3.2. Evaluation	of	toxic	effects	in	CIA	mice	treated	with	tBNPs-MTX	
One	 of	 the	 goals	 of	 this	 project	 is	 to	 demonstrate	 that	 same	 therapeutic	 effects	 can	 be	
obtained	using	a	lower	dose	of	drug	by	targeted	approaches.	As	a	result,	a	lower	dose	of	the	
encapsulated	drug	and	a	different	 route	of	elimination	 (liver-bile-intestine)	 should	coincide	
with	lower	side	effects.	One	of	the	parameters	considered	to	assess	toxicity	is	the	reduction	of	
the	 body	weight	 (Figure	 21	A).	 The	 histogram	 shows	 the	 reduction	 of	 gain	weight	 in	mice	
treated	with	MTX	3mg/	Kg	once	per	week	compared	to	control	mice	and	mice	treated	with	
both	 doses	 of	 tBNPs-MTX.	 Moreover,	 another	 parameter	 used	 to	 demonstrate	 less	 toxic	
effects	 is	based	on	blood	analysis	 (Figure	21	B-G).	Reduction	of	WBC,	RBC	and	PLT	usually	
reflect	toxic	effects	of	the	treatment.	Regarding	WBC,	mice	treated	with	1mg/	Kg	of	MTX	three	
times	 per	 week	 showed	 a	 reduction	 compared	 with	 control	 mice,	 although	 no	 statistical	
significance	has	been	reached.	On	the	contrary,	the	statistical	reduction	has	been	assessed	for	
RBC	and	PLT	in	mice	receiving	this	treatment.	Despite	the	therapeutic	effects	of	this	dose	of	
MTX	some	toxic	effects	were	evident	compared	to	control	animals,	while	mice	treated	with	
both	doses	of	tBNPs-MTX	did	not	show	any	toxic	effects.	A	safe	toxicological	profile	has	been	
also	demonstrated	in	mice	treated	with	a	dose	of	3mg/	Kg	of	MTX.	This	could	be	again	justified	
by	the	fast	elimination	of	the	single	dose.	
Both	gain	weight	and	blood	analysis	highlight	toxic	effects	due	to	the	treatment	with	free	MTX.	
By	contrast,	MTX	encapsulated	in	tBNPs	showed	a	really	safe	profile	in	CIA	mice.		
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information	 that	 can	 be	 obtained,	 it	 is	 difficult	 to	 fully	 understand	 and	 contextualize	 their	
variation	in	the	inflammatory	cells	network	happened	in	this	chronic	model	of	RA.	Moreover,	
these	profiles	concern	the	systemic	cytokines	and	do	not	perfectly	reflect	cytokines	levels	in	
the	 inflamed	 synovia,	where	 the	 local	 profiles	 could	 be	 different.	Moreover,	 cytokines	 act	
through	their	receptors,	which	in	turn	can	be	upregulated	or	downregulated	to	compensate	
cytokines	 low	 expression	 or	 overexpression.	 However,	 cytokines	 quantification	 gives	 a	
reasonable	idea	of	the	inflammatory	landscape	and	should	be	used	as	additional	information	
to	 support	 or	 explain	 other	 data.	 Overall,	 from	 the	 results	 summarized	 in	 figure	 22,	mice	
treated	with	tBNPs-MTX	showed	an	increased	amount	of	IL-1ß,	IL-2,	IL-12p70,	IL-17	and	MIP-
1a	(Figure	22	B,	C,	I,	K,	X).	Despite	the	increased	levels	of	these	cytokines,	the	levels	of	TNF-α,	
which	 is	 the	pivotal	pro-inflammatory	cytokine,	have	been	unchanged	compared	to	control	
mice.	 In	 addition,	 IL-6,	 also	 known	 for	 its	 central	 role	 in	 rheumatoid	 arthritis,	 have	 been	
decreased	as	well	as	RANTES	(regulated	on	activation,	normal	T	cell	expressed	and	secreted).	
The	latter	is	a	chemokine	with	a	chemotactic	role	principally	for	leukocytes.	KC	(keratinocyte-
derived	cytokine)	is	another	chemokine	that	has	been	found	decreased	compared	to	control	
group	of	mice.	This	chemokine	has	neutrophil	chemoattractant	activity	and	has	been	proved	
to	be	involved	in	neoangiogenesis	(Vries	et	al.	2015).		
Due	 to	 the	 therapeutic	 effects	 reached	 in	 the	 group	of	mice	 treated	with	 tBNPs-MTX,	 it	 is	
possible	to	conclude	that,	probably,	the	decrease	levels	of	IL-6,	RANTES	and	KC	could	balance	
the	increased	levels	of	pro-inflammatory	cytokines	such	as	IL-1b,	IL-2,	IL-12p70,	IL-17	and	MIP-
1a.		
Concerning	cytokines	 levels	of	 the	mice	 treated	with	MTX,	cytokines	profile	 is	 substantially	
different	than	tBNPs-MTX,	in	fact	following	cytokines	have	been	increased:	IL-3,	IL-10,	IL-13,	
Eotaxin,	GM-CST,	INF- g,	MCP-1,	MIP-1b	and	most	importantly	TNF-a.	The	increased	levels	of	
these	cytokines	demonstrate	once	again	the	ineffectiveness	of	the	treatment	with	this	dose	of	
MTX.	
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(n=5).	Statistical	significance	has	been	assessed	by	unpaired	parametric	t-test.	P	≤	0.05	=	*;	P	≤	0.01	=	**;	P	≤	0.001	=	***;	P	≤	
0.0001	=	****.	
	
4.4. Mechanism	of	action	of	MTX	encapsulated	into	tBNPs.	
4.4.1. Efficacy	and	side	effects	of	tBNPs-MTX	therapy	in	AIA	rat	
model.	
The	studies	of	biodistribution	prove	the	superior	accumulation	of	the	tBNPs	into	the	inflamed	
knees	of	both	models	of	AIA	and	CIA	compared	with	the	BNPs.	Moreover,	the	superior	efficacy	
of	tBNPs-MTX	has	been	proved	in	CIA	model,	with	a	safer	profile	of	this	treatment	compared	
with	the	free	drug.	However,	we	wondered	if	these	promising	results	were	due	only	to	the	
targeting	strategy,	 thus	a	higher	concentration	of	MTX	 into	 the	synovial	 tissue,	or	whether	
there	 was	 a	 contribution	 of	 a	 different	 mechanism	 of	 action	 of	 the	 drug	 encapsulated	 in	
targeted	nanoparticles.	
In	order	to	dissect	the	mechanism	of	action	of	tBNPs	loaded	with	MTX,	the	treatment	of	the	
AIA	model	has	been	 taken	 in	 consideration	because	 it	 is	 known	 in	 the	 literature	 to	be	not	
treatable	with	free	MTX	(Williams	et	al.	1996)(Williams	2001).	In	fact,	in	this	acute	model,	the	
inflammatory	damage	is	mainly	caused	by	the	production	of	immune	complexes	in	the	joint	
microenvironment,	 by	 the	 activation	 of	 the	 complement	 system	 and	 the	 subsequent	
recruitment	of	immune	cells.	In	this	acute	situation	(3-4	days),	MTX	has	not	the	time	to	reduce	
the	production	of	antibodies	and	its	administration	become	obvious	ineffective.		
Three	groups	of	rats	have	been	enrolled:	5	rats	received	saline	solution	as	control,	4	rats	were	
treated	 with	 MTX	 1	 mg/	 Kg/	 day	 and	 5	 rats	 were	 treated	 with	 tBNPs-MTX	 1mg/Kg.	 The	
treatments	 started	 simultaneously	with	 the	 induction	of	 the	 inflammation.	The	 fourth	day,	
animals	 have	 been	 euthanized	 and	 synovial	 liquids,	 blood	 and	 synovial	 tissue	 have	 been	
collected.	As	the	main	inflammatory	index,	the	swelling	has	been	measured	the	first	and	the	
last	day	in	order	to	calculate	the	∆	reported	in	the	graph	of	the	figure	23	A.	From	this	graph,	it	
is	evident	that	tBNPs-MTX	prevents	the	inflammation	compared	with	both	rats	treated	with	
saline	solution	and	MTX.	Moreover,	to	confirm	swelling	data,	number	of	PMNs	in	the	synovial	
liquid	has	been	evaluated.	Thus,	in	the	figure	23	B,	rats	treated	with	tBNP-MTX	present	a	strong	
decreased	number	of	PMN	cells	compared	with	control	or	MTX	treated	animals.		
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In	order	to	demonstrate	that	the	effects	are	depending	on	the	treatment	and	not	to	a	reduced	
immunization	of	the	animals,	anti-mBSA	IgG	levels	have	been	quantified	in	the	serum	of	these	
animals	(Figure	23	C).	From	this	graph,	it	is	evident	that	all	animals	developed	a	comparable	
immune	response.		
From	the	data	obtained	so	far,	it	is	clear	that	tBNPs-MTX	were	able	to	prevent	inflammation	
in	rat	AIA	where	the	same	dose	of	free	MTX	was	ineffective,	providing	the	indication	that	the	
mechanisms	of	action	of	the	two	therapeutic	approaches	are	different.	
Side	effects	of	these	treatments	should	be	compared	with	data	obtained	in	CIA	model.	For	this	
purpose,	blood	samples	of	the	AIA	rats	have	been	collected	at	the	end	of	the	treatments	(3	
days	treatment)	and	analysed.	RBC,	WBC	and	PLT	have	been	quantified	(Figure	23	D,	E	and	F).	
In	addition,	due	to	the	fact	that	MTX	is	associated	to	the	bone	marrow	suppression	(Lim	et	al.	
2005),	with	consequent	reduction	of	WBC,	subpopulations	of	lymphocytes,	granulocytes	and	
monocytes	have	been	quantified	(Figure	23	G,	H	and	I).	As	expected,	a	significant	reduction	of	
white	blood	cells	has	been	 reported	 in	 the	group	of	 rats	 treated	with	 free	MTX,	while	 rats	
treated	with	the	same	dose	of	tBNPs-MTX	showed	similar	WBC	than	control	rats.	This	result	
highlights	 the	 fact	 that	 in	 our	 approach,	MTX	 remains	mainly	 encapsulated	 into	 tBNPs,	 it	
performs	its	activity	directly	in	the	inflamed	synovia,	decreasing	side	effects	associated	with	a	
non-specific	delivery.	Although	the	total	number	of	WBCs	remained	unchanged	in	rats	treated	
with	 tBNPs-MTX,	 a	 slightly	 reduced	 number	 of	 granulocytes	 have	 been	 found.	 Instead,	 a	
reduction	of	monocytes	has	been	observed	in	both	MTX	and	tBNPs-MTX	treated	groups,	even	
though	no	statistical	significance	has	been	found.		
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Synovial	tissues	have	been	stained	for	the	vWF	in	order	to	verify	this	hypothesis,	analysing	the	
number	of	the	formed	vessel	(Figure	25	A).	In	this	figure,	four	representative	synovial	tissues	
have	been	analysed:	rats	treated	with	saline	solution,	the	synovial	tissue	of	a	healthy	synovia	
(as	 a	 negative	 control),	 rats	 treated	with	both	 tBNPs-MTX	and	 free	MTX.	 It	 is	 evident	 that	
synovial	tissue	of	tBNPs-MTX	treated	rats	shows	a	reduced	vWF	staining,	so	a	reduced	number	
of	blood	vessels,	compared	with	synovial	tissues	of	control	rats	or	rats	treated	with	free	MTX.	
Fluorescence	 intensity	 of	 vWF	 of	 the	 rats	 enrolled	 in	 the	 study	 have	 been	 quantified	 and	
summarized	 in	 the	 graph	 of	 the	 figure	 25	 B.	 The	 graph	 confirms	 a	 reduced	 vWF	 staining	
compared	 with	 control	 rats	 and	 rats	 treated	 with	 free	 MTX.	 This	 result	 strengthens	 our	
hypothesis	by	which	MTX	encapsulated	into	tBNPs	interferes	with	the	formation	of	new	vessels	
in	inflamed	synovium.	It	is	possible	to	speculate	that	the	selective	delivery	of	MTX	to	CD34+	
cells	in	synovial	tissue,	which	is	expressed	on	precursors	of	endothelial	cells,	causes	the	death	
of	these	cells,	reducing	the	possibility	to	develop	new	vessels	in	the	inflamed	synovial	tissue.		
This	process	 is	mandatory	for	the	leukocytes	recruitment	 in	synovial	tissue	and	consequent	
progression	of	inflammation.	The	reduced	number	of	vessels	observed	in	the	inflamed	synovial	
tissues	of	rats	treated	with	tBNPs	may	justify	the	decreased	number	of	inflammatory	cells	such	
as	PMN	and,	at	the	end,	the	reduction	of	the	knee	swelling	observed	in	these	animals	(Figure	
23	B	and	A).		
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Rheumatoid	arthritis	 is	a	chronic	autoimmune	disease	affecting	 joints	due	to	the	persistent	
inflammation	of	 the	 synovial	membrane,	which	 leads	 to	 a	 condition	 of	 disability	 and	pain.	
Despite	 the	 introduction	 of	 biological	 drugs,	which	 improve	 patients’	 quality	 life,	 they	 are	
usually	treated	lifelong	and	true	remission	is	rare.	Moreover,	biological	drugs	show	several	side	
effects	for	long	term	treatments	and	some	patients	do	not	respond	to	this	kind	of	treatments.	
For	these	reasons	MTX,	belonging	to	the	synthetic	DMARDs	class,	is	still	the	cornerstone	of	RA	
treatment	because	of	its	safe	profile,	effectiveness	and	low	cost.	However,	some	issues	arise	
with	MTX	treatment	due	to	the	fact	that	50%	of	patients,	after	5	years	have	to	discontinue	the	
treatment	 because	 of	 inefficacy	 or	 side	 effects	 such	 as	 liver	 toxicity	 and	 bone	 marrow	
suppression.	 According	 to	 the	 ACR	 criteria,	 early	 diagnosis	 is	 essential	 for	 a	 successful	
management	in	order	to	treat	patients	as	soon	as	possible	avoiding	late	phase	(disability)	of	
the	disease.		
The	attention	of	our	group	was	recently	focused	on	the	development	of	a	nanotechnological	
approach	to	treat	and	diagnose	RA	with	a	higher	efficacy	and	specificity.	This	strategy	is	based	
on	the	use	of	polymeric	biodegradable	nanoparticles	able	to	target	in	a	specific	manner	the	
inflamed	 synovial	 tissue	 due	 to	 targeting	 molecules	 conjugated	 on	 the	 surface	 of	 these	
nanoparticles.	Exploiting	this	strategy,	their	payload	can	be	accumulated	into	the	desired	place	
avoiding	toxic	effects	related	to	systemic	administration.		
In	this	research	project,	two	different	couples	of	nanoparticles	have	been	produced:	a	couple	
of	empty	nanoparticles,	with	(tBNPs)	and	without	(BNPs)	the	targeting	molecule,	and	a	couple	
of	 MTX	 loaded	 nanoparticles,	 with	 (tBNPs-MTX)	 and	 without	 (BNPs-MTX)	 the	 targeting	
molecule.		
All	different	nanoparticles	have	been	characterized	by	DLS,	TEM,	STEM	and	NanoTrack	in	order	
to	assess	their	size	distribution,	diameter,	PDI,	charge	and	nanoparticles	concentration.	They	
showed	an	average	diameter	of	about	150nm	with	a	PDI	of	0.3	and	a	slight	negative	charge	of	
-6mV.	These	characteristics	were	designed	for	an	ideal	distribution	in	vivo,	 in	particular	the	
size	is	large	enough	to	ensure	high	doses	of	the	loaded	compound	and,	at	the	same	time,	allow	
a	good	distribution	within	the	body.	Moreover,	the	low	negative	charge	avoids	the	interaction	
with	several	positive	basal	membranes	(like	in	kidneys	and	lungs)	and	in	general	with	cells.	
The	 biocompatibility	 of	 the	 shell’s	 nanoparticles	 has	 been	 tested	 showing	 that	 empty	
nanoparticles,	with	and	without	the	targeting	molecule,	did	not	show	toxicity	for	cells.	MTX	
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release	has	been	measured	demonstrating	that	50%	of	the	drug	was	still	encapsulated	into	
nanoparticles	after	24h.		
The	 importance	 of	 a	 targeting	 agent	 on	 nanoparticles’	 surface	 is	 still	 debated.	 Our	 data,	
obtained	both	in	vitro	and	in	vivo	clearly	evidenced	the	increased	ability	of	tBNPs	to	selectively	
accumulate	into	inflamed	synovial	tissue.	In	particular,	tBNPs	showed	a	higher	accumulation	
in	the	inflamed	joints	compared	to	BNPs	in	two	different	animal	models.	
Despite	the	differences	seen	in	the	animal	models,	it	is	evident	that	tBNPs	are	promising	as	a	
diagnostic	delivery	system	able	to	potentially	increase	the	accumulation	of	a	diagnostic	probe	
and,	as	a	consequence,	the	sensitivity	of	several	imaging	techniques.	Targeted	nanobubbles	
through	 the	 synovial	 peptide	will	 represent	 a	 potential	 probe	 for	 functional	 imaging	 using	
ultrasound,	as	well	as	 targeted	nanoparticles	 loaded	with	contrast	agents	may	be	useful	 in	
NMR	o	x-ray-based	approaches.		
The	 capacity	 of	 tBNP	 to	 accumulate	 in	 joints	 during	 the	 early	 phase	 of	 the	 inflammatory	
process,	when	no	phenotypic	evidence	of	the	pathology	is	detectable,	encourage	our	study	to	
develop	a	diagnostic	probe	for	early	diagnosis.	Moreover,	the	capacity	to	discriminate	different	
degree	of	inflammation	will	provide	the	basis	to	use	the	same	probe	to	follow	the	effectiveness	
of	the	therapy	in	use.		
The	core	of	the	project	was	to	demonstrate	that	tBNPs,	which	combine	the	active	targeting	
with	 the	 nanoparticles	 features,	 could	 provide	 a	 new	 therapeutic	 approach	 through	 the	
selective	accumulation	of	MTX	in	the	inflamed	synovial	microenvironment.	To	reach	this	aim,	
tBNP-MTX	efficacy	has	been	first	studied	in	CIA	mouse	model	and	then	in	and	AIA	rat	model.	
Results	demonstrated	that	tBNPs-MTX	showed	similar	outcome	than	free	MTX,	using	the	same	
total	weekly	dose	but	also	reducing	the	dose	of	encapsulated	MTX	to	1/3,	administering	it	once	
per	week.	Moreover,	 the	 therapeutic	effects	were	also	associated	with	a	 safe	 toxicological	
profile.	
Part	of	this	work	has	been	dedicated	to	identifying	the	counterpart	of	the	targeting	molecule.	
Indeed,	 from	 the	 literature,	 it	 is	 known	 that	 the	 synovial	 homing	 peptide	 binds	 the	
microvasculature	 of	 the	 inflamed	 synovial	 tissue,	 although	 the	 bound	molecule	 is	 not	 yet	
recognized.	Co-staining	immunofluorescence	performed	with	the	target	molecule	and	markers	
of	 endothelial	 tissues	 evidenced	 that	 the	 target	molecule	 localizes	 onto	 CD34+	 cells.	 Cells	
expressing	CD34	in	synovial	tissue	are	mainly	progenitors	of	endothelial	cells	and	this	evidence	
was	fundamental	to	first	hypothesize	and	then	demonstrate	a	different	mechanism	of	action	
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of	 MTX	 once	 encapsulated	 into	 tBNPs.	 Due	 to	 the	 fact	 that	 nanoparticles	 impacted	 on	
endothelial	cells,	we	speculate	that	MTX	(initially	 isolated	as	a	cytotoxic	drug)	could	 induce	
CD34+	cell	death	and,	as	a	consequence,	has	an	anti-neoagiogenetic	effect.	On	the	contrary,	
free	MTX	usually	plays	its	anti-inflammatory	effect	reducing	the	number	of	B	and	T	cells	and	
increasing	adenine	and	adenosine	into	the	extracellular	space.	The	formation	of	new	vessels	is	
essential	for	leukocytes	migration	and	synovial	tissue	infiltration;	the	reduction	of	leukocytes	
in	 synovial	microenvironment	 brings	 to	 a	 reduction	 of	 the	 inflammatory	 process.	 This	was	
particularly	 evident	 in	 an	 AIA	 rat	 model,	 where	 free	 MTX	 was	 ineffective.	 However,	 the	
formation	of	new	vessels	in	synovial	tissue	was	reduced	using	tBNP-MTX,	preventing	the	onset	
of	the	pathology.		
This	work	 introduces	 an	 innovative	 approach	 to	diagnose	and	 treat	RA,	 based	on	 targeted	
polymeric	nanoparticles	able	to	deliver	their	payloads	to	the	microvasculature	of	the	inflamed	
synovial	 tissue.	This	nanotechnological	system	due	to	the	active	targeting	shows	enormous	
potential	increasing	sensitivity	as	a	diagnostic	tool	and	simultaneously	enhancing	therapeutic	
effects	and	reducing	doses	and	related	side	effects.	The	focus	of	this	study	was	to	improve	the	
management	of	patients	affected	by	RA.	However,	several	other	articular	pathologies,	where	
neo-angiogenesis	plays	a	pivotal	role	in	the	inflammatory	process,	can	exploit	the	potential	of	
tBNPs.	Osteoarthritis	is	probably	the	first	pathology	where	tBNPs	can	find	application,	indeed	
its	treatment	remains	an	unmet	clinical	need.	Moreover,	the	ability	of	the	targeting	peptide	to	
cross-react	 with	mouse,	 rat	 and	 human	 inflamed	 synovial	 tissue	 suggest	 the	 possibility	 to	
extend	the	use	of	tBNPs	to	dogs	and	horses,	in	which	articular	disorders	are	common,	in	order	
to	provide	a	new	therapeutic	approach	and	to	collect	several	preclinical	data	before	the	first	
use	in	human.	
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